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[571 ABSTRACT 
The present invention discloses deoxyribonucleic acid 
enzymesdatalytic or enzymatic DNA molecules-capable 
of cleaving nucleic acid sequences or molecules, particularly 
RNA, in a site-specific manner, as well as compositions 
including same. Methods of making and using the disclosed 
enzymes and compositions are also disclosed. 
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ENZYMATIC DNA MOLECULES 
CROSS-REFERENCE TO RELATED 
APPLI CAT1 ON 
Guerrier-Takada, et al., Cell 35: 849-857 (1983)). The list of 
known naturally-occurring ribozymes continues to grow 
(see Cech, in The RNA World, Gesteland & Atkins (eds.), pp. 
239-269, Cold Spring Harbor Laboratory Press, Cold 
s Spring Harbor, N.Y. (1993); Pyle, Science 261: 709-714 
(1993); Symons, Cum Opin. Struct. Biol. 4: 322-330 
(1994)) and, in recent years, has been augmented by syn- 
thetic ribozymes obtained through in vitro evolution. (See, 
Breaker & J ~ ~ ~ ~ ,  Trends Biotech. 12: 268-275 (1994); 
Chapman & Szostak, Cur% Onin. Struct. Biol. 4: 618-622 
(1 9 94) .) 
It seems reasonable to assume that DNA can have cata- 
The present invention relates to nucleic acid enzymes or lytic activity as well, considering that it contains most of the 
catalytic (enzymatic) DNA molecules that are capable of 15 same functional groups as RNA. However, with the excep- 
cleaving RNA. The present invention also relates to com- tion of certain viral genomes and replication intermediates, 
positions containing the disclosed enzymatic DNA mol- nearly all of the DNA in biological organisms occurs as a 
ecules and to methods of making and using such enzymes complete duplex, precluding it from adopting a complex 
and compositions. secondary and tertiary structure. Thus it is not surprising that 
Until the advent of the present invention, the design, 
The need for catalysts that operate outside of their native synthesis and use of catalytic DNA molecules with 
context or which catalyze reactions that are not represented nucleotide-cleaving capabilities has not been disclosed or 
in nature has resulted in the development of “enzyme demonstrated. Therefore, the discoveries and inventions 
engineering” technology. The usual route taken in enzyme 25 disclosed herein are particularly significant, in that they 
engineering has been a “rational design” approach, relying highlight the potential of in vitro evolution as a means of 
upon the understanding of natural enzymes to aid in the designing increasingly more efficient catalytic molecules, 
construction of new enzymes. Unfortunately, the state of including enzymatic DNA molecules that cleave other 
This is a continuation-in-part of U.S. application Ser. No. 
081349,023, filed Dec. 2,1994, abandoned the disclosures of 
which are incorporated by reference herein. 
NASAGrant No. NAGW-3118. The government has certain 
rights in the invention. 
This invention was made with government support under e.g., Joyce, Curv. Opin. Struct. Bioi. 4: 331-336 (1994); 
TECHNICAL FIELD 
20 DNA enzymes have not been found in nature. 
BACKGROUND 
proficiency in the areas 0; protein structure and chemistry is 
insufficient to make the generation of novel biological 30 
catalvsts routine. 
nucleic acids, particularly RNA. 
BRIEF SUMMARY OF THE INVENTION 
Recently, a different approach for developing novel cata- The Present invention thus contemplates a synthetic (i.e., 
lysts has been applied. This method involves the construc- non-naturally-occurring) catalytic DNA molecule (Or enzY- 
tion of a heterogeneous pool of macromolecules and the matic DNA molecule) capable of cleaving a substrate 
application of an in vitro selection procedure to isolate 35 nucleic acid sequence at a defined cleavage site. The inven- 
molecules from the pool that catalyze the desired reaction. tion also contemplates an enzymatic DNAmolecule having 
Selecting catalysts from a pool of macromolecules is not an endonuclease activity. 
dependent on a comprehensive understanding of their struc- In one preferred variation, the endonuclease activity is 
tural and chemical properties. Accordingly, this process has 4o specific for a nucleotide sequence defining a cleavage site 
been dubbed “irrational design” (Brenner and Lerner, PNAS comprising single-stranded nucleic acid in the substrate 
USA 89: 5381-5383 (1992)). nucleic acid sequence. In another preferred variation, the 
Most efforts to date involving the rational design of cleavage site is a double-stranded nucleic acid. 
enzymatic RNA molecules or ribozymes have not led to In another contemplated embodiment, the substrate 
molecules with fundamentally new or improved catalytic 45 nucleic acid sequence includes one or more nucleotide 
function. However, the application of irrational design meth- analogues. In one variation, the substrate nucleic acid 
ods via a process we have described as “directed molecular sequence is a portion of a larger molecule. 
evolution” or “in vitro evolution”, which is patterned after In various embodiments, the larger molecule is selected 
Darwinian evolution of organisms in nature, has the poten- from the group consisting of RNA, modified RNA, DNA, 
tial to lead to the production of DNA molecules that have modified DNA, nucleotide analogs, or composites thereof. 
desirable functional characteristics. In another example, the larger molecule comprises a com- 
This technique has been applied with varying degrees of posite of a nucleic acid sequence and a non-nucleic acid 
success to RNAmolecules in solution (see, e.g., Mills, et al., sequence. 
PNAS USA 58: 217 (1967); Green, et al., Nature 347: 406 In another embodiment, the invention contemplates that a 
(1990); Chowrira, et al., Nature 354: 320 (1991); Joyce, 5s substrate nucleic acid sequence includes one or more nucle- 
Gene 82: 83 (1989); Beaudry and Joyce, Science 257: otide analogs. A further variation contemplates that the 
635-641 (1992); Robertson and Joyce, Nature 344: 467 single stranded nucleic acid comprises RNA, DNA, modi- 
(1990)), as well as to RNAs bound to a ligand that is fied RNA, modified DNA, one or more nucleotide analogs, 
attached to a solid support (Tuerk, et al., Science 249: 505 or any composite thereof. In one embodiment of the dis- 
(1990); Ellington, et al., Nature 346: 818 (1990)). It has also 60 closed invention, the endonuclease activity comprises 
been applied to peptides attached directly to a solid support hydrolytic cleavage of a phosphoester bond at the cleavage 
(Lam, et al., Nature 354: 82 (1991)); and to peptide epitopes site. 
expressed within a viral coat protein (Scott, et al., Science In various preferred embodiments, the catalytic DNA 
249: 386 (1990); D e v k  et al., &imce 249: 249 (1990); molecules of the present invention are single-stranded. 
Cwirla, et al., PNAS USA 87: 6378 (1990)). 65 These catalytic DNA molecules may preferably assume a 
It has been more than a decade since the discovery of variety of shapes consistent with their catalytic activity. 
catalytic RNA (Kruger, et al., Cell 31: 147-157 (1982); Thus, in one variation, a catalytic DNA molecule of the 
5,807,718 
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present invention includes one or more hairpin loop stmc- 
tures. In yet another variation, a catalytic DNA molecule 
may assume a shape similar to that of “hammerhead” 
ribozymes. 
Similarly, preferred catalytic DNA molecules of the 
present invention are able to demonstrate site-specific endo- 
nuclease activity irrespective of the original orientation of 
the substrate molecule. That is, in one preferred 
embodiment, an enzymatic DNA molecule of the present 
invention is able to cleave a substrate nucleic acid sequence 
that is separate from the enzymatic DNA molecule-i.e., it 
is not linked to the DNAzyme. In another preferred 
embodiment, an enzymatic DNA molecule is able to cleave 
an attached substrate nucleic acid sequence-i.e., it is able 
to perform a type of self-cleavage. 
The invention also contemplates enzymatic DNA mol- 
ecules (catalytic DNA molecules or DNAzymes) having 
endonuclease activity, whereby the endonuclease activity 
requires the presence of a divalent cation. In various 
preferred, alternative embodiments, the divalent cation is 
selected from the group consisting of Pb2+, Mg2+, Mn”, 
Zn”, and Ca”. Another variation contemplates that the 
endonuclease activity requires the presence of a monovalent 
cation. In such alternative embodiments, the monovalent 
cation is preferably selected from the group consisting of 
Na’and K+. 
In various preferred embodiments of the invention, an 
enzymatic DNA molecule comprises a nucleotide sequence 
selected from the group consisting of SEQ ID NO 3, SEQ ID 
NO 14; SEQ ID NO 15; SEQ ID NO 16; SEQ ID NO 17; 
SEQ ID NO 18; SEQ ID NO 19; SEQ ID NO 20; SEQ ID 
NO 21; and SEQ ID NO 22. In other preferred embodiments, 
a catalytic DNAmolecule of the present invention comprises 
a nucleotide sequence selected from the group consisting of 
SEQ ID NO 23; SEQ ID NO 24; SEQ ID NO 25; SEQ ID 
NO 26; SEQ ID NO 27; SEQ ID NO 28; SEQ ID NO 29; 
SEQ ID NO 30; SEQ ID NO 31; SEQ ID NO 32; SEQ ID 
NO 33; SEQ ID NO 34; SEQ ID NO 35; SEQ ID NO 36; 
SEQ ID NO 37; SEQ ID NO 38; and SEQ ID NO 39. 
In a further variation of the present invention, an enzy- 
matic DNAmolecule of the present invention preferably has 
a substrate binding affinity of about 1 pM or less. In another 
embodiment, an enzymatic DNA molecule of the present 
invention binds substrate with a KD of less than about 0.1 
The present invention also contemplates an embodiment 
whereby the nucleotide sequence defining the cleavage site 
comprises at least one nucleotide. In various other preferred 
embodiments, a catalytic DNA molecule of the present 
invention is able to recognize and cleave a nucleotide 
sequence defining a cleavage site of two or more nucle- 
otides. 
In various preferred embodiments, an enzymatic DNA 
molecule of the present invention comprises a conserved 
core flanked by one or more substrate binding regions. In 
one embodiment, an enzymatic DNAmolecule includes first 
and second substrate binding regions. In another 
embodiment, an enzymatic DNA molecule includes two or 
more substrate binding regions. 
As noted previously, preferred catalytic DNA molecules 
of the present invention also include a conserved core. In 
one preferred embodiment, the conserved core comprises 
one or more conserved regions. In other preferred variations, 
the one or more conserved regions include a nucleotide 
sequence selected from the group consisting of CG; CGA, 
AGCG; AGCCG; CAGCGAT; CTTGTTT; and CTTATTT. 
PM. 
4 
In one embodiment of the invention, an enzymatic DNA 
molecule of the present invention further comprises one or 
more variable or spacer nucleotides between the conserved 
regions in the conserved core. In another embodiment, an 
5 enzymatic DNA molecule of the present invention further 
comprises one or more variable or spacer nucleotides 
between the conserved core and the substrate binding 
region. 
In one variation, the first substrate binding region pref- 
erably includes a nucleotide sequence selected from the 
group consisting of CATCTCT; GCTCT; TTGCTTTTT; 
TGTCTTCTC; TTGCTGCT; GCCATGCTTT (SEQ ID NO 
19, residues 5-14); CTCTATTTCT (SEQ ID NO 20, resi- 
dues l(r19); GTCGGCA, CATCTCTTC; and ACTTCT. In 
another preferred variation, the second substrate binding 
region includes a nucleotide sequence selected from the 
group consisting of TATGTGACGCTA (SEQ ID NO 14, 
residues 28-39); TATAGTCGTA (SEQ ID NO 15, residues 
41-50); ATAGCGTATTA(SEQ ID NO 16, residues 40-50); 
ATAGTTACGTCAT (SEQ ID NO 17, residues 27-39); 
2o AATAGTGAAGTGTT (SEQ ID NO 18, residues 28-41); 
TATAGTGTA, ATAGTCGGT; ATAGGCCCGGT (SEQ ID 
NO 21, residues 4(r50); AATAGTGAGGCTTG (SEQ ID 
NO 22, residues 36-49); and ATGNTG. 
In another preferred embodiment, a catalytic DNA mol- 
ecule of the present invention may further comprise a third 
substrate binding region. In some preferred embodiments, 
the third region includes a nucleotide sequence selected 
from the group consisting of TGTT; TGTTA, and TGTTAG. 
Another preferred embodiment of the present invention 
discloses an enzymatic DNA molecule further comprising 
one or more variable or “spacer” regions between the 
substrate binding regions. 
In another disclosed embodiment, the present invention 
3s contemplates a purified, synthetic enzymatic DNA molecule 
separated from other DNA molecules and oligonucleotides, 
the enzymatic DNA molecule having an endonuclease 
activity, wherein the endonuclease activity is specific for a 
nucleotide sequence defining a cleavage site comprising 
4o single-stranded nucleic acid in a substrate nucleic acid 
sequence. In one variation, a synthetic enzymatic DNA 
molecule having an endonuclease activity is disclosed, 
wherein the endonuclease activity is specific for a nucleotide 
sequence defining a cleavage site consisting essentially of a 
4s single-stranded region of a substrate nucleic acid sequence. 
In yet another embodiment, the invention contemplates an 
enzymatic DNA molecule comprising a deoxyribonucle- 
otide polymer having a catalytic activity for hydrolyzing a 
nucleic acid-containing substrate to produce substrate cleav- 
so age products. In one variation, the hydrolysis takes place in 
a site-specific manner. In another variation, the polymer is 
single-stranded; another embodiment contemplates that the 
substrate includes a single-stranded segment. 
The invention further contemplates that the substrate 
5s comprises a nucleic acid sequence. In various embodiments, 
the nucleic acid sequence substrate comprises RNA, modi- 
fied RNA, DNA, modified DNA, one or more nucleotide 
analogs, or composites of any of the foregoing. 
The present invention further contemplates an enzymatic 
60 DNA molecule comprising a deoxyribonucleotide polymer 
having a catalytic activity for hydrolyzing a nucleic acid- 
containing substrate to produce a cleavage product. In one 
variation, the enzymatic DNA molecule has an effective 
binding affinity for the substrate and lacks an effective 
In one preferred embodiment, the invention discloses a 
non-naturally-occurring enzymatic DNA molecule compris- 
2s 
30 
65 binding affinity for the cleavage product. 
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ing a nucleotide sequence defining a conserved core flanked 
by recognition domains, variable regions, and spacer 
regions. Thus, in one preferred embodiment, the nucleotide 
sequence defines a first variable region contiguous or adja- 
cent to the 5'-terminus of the molecule, a first recognition 
domain located 3'-terminal to the first variable region, a first 
spacer region located 3'-terminal to the first recognition 
domain, a first conserved region located 3'-terminal to the 
first spacer region, a second spacer region located 
3'-terminal to the first conserved region, a second conserved 
region located 3'-terminal to the second spacer region, a 
second recognition domain located 3'-terminal to the second 
conserved region, and a second variable region located 
3'-terminal to the second recognition domain. 
In another embodiment, the nucleotide sequence prefer- 
ably defines a first variable region contiguous or adjacent to 
the 5'-terminus of the molecule, a first recognition domain 
located 3'-terminal to the first variable region, a first spacer 
region located 3'-terminal to the first recognition domain, a 
first conserved region located 3'-terminal to the first spacer 
region, a second spacer region located 3'-terminal to the first 
conserved region, a second conserved region located 
3'-terminal to the second spacer region, a second recognition 
domain located 3'-terminal to the second conserved region, 
a second variable region located 3'-terminal to the second 
recognition domain, and a third recognition domain located 
3'-terminal to the second variable region. 
In one variation of the foregoing, the molecule includes a 
conserved core region flanked by two substrate binding 
domains; in another, the conserved core region comprises 
one or more conserved domains. In other preferred 
embodiments, the conserved core region further comprises 
one or more variable or spacer nucleotides. In yet another 
embodiment, an enzymatic DNA molecule of the present 
invention further comprises one or more spacer regions. 
The present invention further contemplates a wide variety 
of compositions. For example, compositions including an 
enzymatic DNA molecule as described hereinabove are 
disclosed and contemplated herein. In an alternative 
embodiment, a composition according to the present inven- 
tion comprises two or more populations of enzymatic DNA 
molecules as described above, wherein each population of 
enzymatic DNA molecules is capable of cleaving a different 
sequence in a substrate. In another variation, a composition 
comprises two or more populations of enzymatic DNA 
molecules as described hereinabove, wherein each popula- 
tion of enzymatic DNA molecules is capable of recognizing 
a different substrate. In various embodiments, it is also 
preferred that compositions include a monovalent or diva- 
lent cation. 
The present invention further contemplates methods of 
generating, selecting, and isolating enzymatic DNA mol- 
ecules of the present invention. In one variation, a method of 
selecting enzymatic DNA molecules that cleave a nucleic 
acid sequence (e.g., RNA) at a specific site, comprises the 
following steps: (a) obtaining a population of synthetic, 
single-stranded DNA molecules; (b) admixing nucleotide- 
containing substrate sequences with the population of 
single-stranded DNA molecules to form an admixture; (c) 
maintaining the admixture for a sufficient period of time and 
under predetermined reaction conditions to allow single- 
stranded DNA molecules in the population to cause cleavage 
of the substrate sequences, thereby producing substrate 
cleavage products; (d) separating the population of single- 
stranded DNA molecules from the substrate sequences and 
substrate cleavage products; and (e) isolating single- 
stranded DNA molecules that cleave substrate nucleic acid 
sequences (e.g., RNA) at a specific site from the population. 
6 
In a further variation of the foregoing method, the DNA 
molecules that cleave substrate nucleic acid sequences at a 
specific site are tagged with an immobilizing agent. In one 
example, the agent comprises biotin. 
The invention also contemplates methods as described 
above, wherein the isolating step further comprises exposing 
the tagged DNA molecules to a solid surface having avidin 
linked thereto, whereby the tagged DNA molecules become 
attached to the solid surface. As before, the substrate may be 
10 RNA, DNA, a composite of both, or a molecule including 
nucleotide sequences. 
The present invention also contemplates a method for 
specifically cleaving a substrate nucleic acid sequence at a 
particular cleavage site, comprising the steps of (a) provid- 
ing an enzymatic DNA molecule capable of cleaving a 
substrate nucleic acid sequence at a specific cleavage site; 
and (b) contacting the enzymatic DNA molecule with the 
substrate nucleic acid sequence to cause specific cleavage of 
the nucleic acid sequence at the cleavage site. In one 
2o variation, the enzymatic DNA molecule is a non-naturally- 
occurring (or synthetic) DNAmolecule. In another variation, 
the enzymatic DNA molecule is single-stranded. 
In still another variation, of the foregoing method, the 
25 substrate comprises a nucleic acid. In various embodiments, 
the substrate nucleic acid comprises RNA, modified RNA, 
DNA, modified DNA, one or more nucleotide analogs, or 
composites of any of the foregoing. In yet another 
embodiment, the specific cleavage is caused by the endo- 
The present invention also contemplates a method of 
cleaving a phosphoester bond, comprising (a) admixing an 
catalytic DNA molecule capable of cleaving a substrate 
nucleic acid sequence at a defined cleavage site with a 
35 phosphoester bond-containing substrate, to form a reaction 
admixture; and (b) maintaining the admixture under prede- 
termined reaction conditions to allow the enzymatic DNA 
molecule to cleave the phosphoester bond, thereby produc- 
ing a population of substrate products. In one embodiment, 
4o the enzymatic DNAmolecule is able to cleave the phospho- 
ester bond in a site-specific manner. In another embodiment, 
the method further comprises the steps of (c) separating the 
products from the catalytic DNA molecule; and (d) adding 
additional substrate to the enzymatic DNA molecule to form 
The present invention also contemplates methods of engi- 
neering enzymatic DNA molecules that cleave phosphoester 
bonds. One exemplary method comprises the following 
steps: (a) obtaining a population of single-stranded DNA 
50 molecules; (b) introducing genetic variation into the popu- 
lation to produce a variant population; (c) selecting indi- 
viduals from the variant population that meet predetermined 
selection criteria; (d) separating the selected individuals 
from the remainder of the variant population; and (e) ampli- 
5 
3o nuclease activity of the enzymatic DNA molecule. 
45 a new reaction admixture. 
5s fying the selected individuals. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates a selective amplification scheme for 
isolation of DNAs that cleave a target RNAphosphoester. As 
60 shown, double-stranded DNA that contains a stretch of 50 
random nucleotides (the molecule with ''N50'' indicated 
above it) is amplified by PCR, employing a 5'-biotinylated 
DNA primer that is terminated at the 3'end by an adenosine 
ribonucleotide (rA). (The biotin label is indicated via the 
65 encircled letter "B".) This primer is extended by Taq poly- 
merase to yield a DNA product that contains a single 
embedded ribonucleotide. The resulting double-stranded 
5,807,718 
7 8 
DNA is immobilized on a streptavidin matrix and the As noted, there are three lanes within each of the afore- 
unbiotinylated DNA strand is removed by washing with mentioned four groups. In each group of three lanes, the first 
0.2N NaOH. After re-equilibrating the column with a buff- lane shows the lack of activity of the selected population in 
ered solution, the column is washed with the same solution the absence of the metal cation, the second lane shows the 
with added 1 mM PbOAc. DNAs that undergo Pb2+- s observed activity in the presence of the metal cation, and the 
dependent self-cleavage are released from the column, col- third lane shows the lack of activity of the starting pool (GO). 
lected in the eluant, and amplified by PCR. The PCR FIGS. 6Aand 6B provide two-dimensional illustrations of 
products are then used to initiate the next round of selective a “progenitor” catalytic DNA molecule and one of several 
amplification. catalytic DNA molecules obtained via the selective ampli- 
FIG. 2 illustrates self-cleavage activity of the starting pool 10 fication methods disclosed herein, respectively. FIG. 6A 
of DNA(G0) and populations obtained after the first through illustrates an exemplary molecule from the starting pool, 
fifth rounds of selection (Gl-G5), in the presence of lead showing the overall configuration of the molecules repre- 
cation (Pb”). The symbol Pre represents 108-nucleotide sented by SEQ ID NO 23. As illustrated, various comple- 
precursor DNA (SEQ ID NO 4); Clv, 28-nucleotide mentary nucleotides flank the random (NdO) region. FIG. 6B 
5’-cleavage product (SEQ ID NO 5); and M, primer 3a (SEQ 1s is a diagrammatic representation of one of the Mg2+- 
ID NO 6), which corresponds in length to the 5’-cleavage dependent catalytic DNAmolecules (or “DNAzymes”) gen- 
product. erated via the within-described procedures (SEQ ID NO 40). 
FIG, 3 illustrates the sequence alignment of individual The location of the ribonucleotide in the substrate nucleic 
variants isolated from the popu~ation after five rounds of acid is indicated via the arrow in both FIGS. 6A and 6B. 
DETAILED DESCRIPTION selection. The fixed substrate domain is shown at the top, 2o 
with the target riboadenylate identified via an inverted 
triangle. Substrate nucleotides that are commonly involved A. Definitions 
in presumed base-pairing interactions are indicated by ver- As used herein, the term “deoxyribozyme” is used to 
tical bars. Sequences corresponding to the 50 initially- describe a DNA-containing nucleic acid that is capable of 
randomized nucleotides are aligned antiparallel to the sub- 2s functioning as an enzyme. In the present disclosure, the term 
strate domain. All of the variants are 3’-terminated by the “deoxyribozyme” includes endoribonucleases and 
fixed sequence 5’-CGGTAAGCTTGGCAC-3’(not shown; endodeoxyribonucleases, although deoxyribozymes with 
SEQ ID NO 1). Nucleotides within the initially-randomized endoribonuclease activity are particularly preferred. Other 
region that are presumed to form base pairs with the sub- terms used interchangeably with deoxyribozyme herein are 
strate domain are indicated on the right and left sides of the 30 “enzymatic DNA molecule” or “catalytic DNA molecule”, 
Figure; the putative base-pair-forming regions of the enzy- which should be understood to include enzymatically active 
matic DNA molecules are individually boxed in each portions thereof, whether they are produced synthetically or 
sequence shown. Conserved regions are illustrated via the derived from organisms or other sources. 
two large, centrally-located boxes. The term “enzymatic DNAmolecules” also includes DNA 
FIGS. 4A and 4B illustrate DNA-catalyzed cleavage of an molecules that have complementarity in a substrate-binding 
RNA phosphoester in an intermolecular reaction that pro- region to a specified oligonucleotide target or substrate; it 
ceeds with catalytic turnover. FIG. 4A is a diagrammatic also has an enzymatic activity which is active to specifically 
representation of the complex formed between the 19mer cleave the oligonucleotide substrate. Stated in another 
substrate (3’-TCACTATrAGGAAGAGATGG-5’, SEQ ID 4o fashion, the enzymatic DNAmolecule is capable of cleaving 
N 0 2 )  a n d  3 8 m e  r D N A  e n z y  m e (5 ’ - the oligonucleotide substrate intermolecularly. This comple- 
ACACATCTCTGAAGTAGCGCCGCCGTATAGTGACG mentarity functions to allow sufficient hybridization of the 
CTA-3’, SEQ ID NO 3). The substrate contains a single enzymatic DNAmolecule to the substrate oligonucleotide to 
adenosine ribonucleotide (‘‘rN’, adjacent to the arrow), allow the intermolecular cleavage of the substrate to occur. 
3s 
flanked by deoxyribonucleotides. The synthetic DNA 4s While one-hundred percent (100%) complementarity is 
enzyme is a 38-nucleotide portion of the most frequently preferred, complementarity in the range of 75-100% is also 
occurring variant shown in FIG. 3. Highly-conserved nucle- useful and contemplated by the present invention. 
otides located within the putative catalytic domain are Enzymatic DNA molecules of the present invention may 
“boxed”. As illustrated, one conserved sequence is alternatively be described as having nuclease or ribonu- 
“AGCG’, while another is “CG’ (reading in the 5’+3’ so clease activity. These terms may be used interchangeably 
direction). herein. 
FIG. 4B shows an Eadie-Hofstee plot used to determine The term “enzymatic nucleic acid” as used herein encom- 
K, (negative slope) and V, (y-intercept) for DNA- passes enzymatic RNAor DNAmolecules, enzymatic RNA- 
catalyzed cleavage of [5’-32P]-labeled substrate under con- DNApolymers, and enzymatically active portions or deriva- 
ditions identical to those employed during in vitro selection. 5s tives thereof, although enzymatic DNA molecules are a 
Initial rates of cleavage were determined for reactions particularly preferred class of enzymatically active mol- 
involving 5 nM DNAenzyme and either 0.125,0.5, l ,  2, or ecules according to the present invention. 
4 pM substrate. The term “endodeoxyribonuclease”, as used herein, is an 
FIG. 5 is a photographic representation showing a poly- enzyme capable of cleaving a substrate comprised predomi- 
acrylamide gel demonstrating specific endoribonuclease 60 nantly of DNA. The term “endoribonuclease”, as used 
activity of four families of selected catalytic DNAs. Selec- herein, is an enzyme capable of cleaving a substrate com- 
tion of a Pb2+-dependent family of molecules was repeated prised predominantly of RNA. 
in a side-by-side fashion as a control (first group). In the As used herein, the term “base pair”(bp) is generally used 
second group, Zn2+ is used as the cation; in group three, the to describe a partnership of adenine (A) with thymine (T) or 
cation is Mn”; and in the fourth group, the cation is Mg2+. 65 uracil (U), or of cytosine (C) with guanine (G), although it 
Afifth site on the gel consists of the cleavage product alone, should be appreciated that less-common analogs of the bases 
as a marker. A, T, C, and G may occasionally participate in base pairings. 
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Nucleotides that normally pair up when DNA or RNA new enzymatic DNA molecule containing the mutations of 
adopts a double stranded configuration may also be referred both molecules. 
to herein as “complementary bases”. In other preferred embodiments, an enzymatic DNA mol- 
  complementary nucleotide sequence” generally refers to ecule of the present invention may have random mutations 
a sequence of nucleotides in a single-stranded molecule of 5 introduced into it using a variety of methods well known to 
DNA or RNA that is comp~ementary to that on those skilled in the art. For example, the method described 
another single oligonucleotide strand to specifically hybrid- by Cadwe’’ and Joyce (pcR and Appzications 2: 
28-33 (1992)) is particularly preferred for use as disclosed ize to it with consequent hydrogen bonding. herein, with some modifications, as described in the 
generally refers to a monomeric Of Examples that follow, (Also see Cadwell and Joyce, PCR 
DNA Or RNA Of a sugar moiety (pentose), a lo Methods andApplicatiom 3 (Suppl.): S136S140 (1994).) 
Phosphate group, and a nitrogenous heterocyclic base. The According to this modified PCR method, random point 
base is linked to the sugar moiety via the glycosidic carbon mutations may be introduced into cloned genes, 
(l’carbon of the pentose) and that combination of base and to mutagenize 
sugar is a “nucleoside”. When the nucleoside contains a the gene encoding the ribozyme with a mutation rate of 
Phosphate group bonded to the 3’ Or 5’ Position of the 0.66%+0.13% (95% confidence interval) per position, as 
pentose, it is referred to as a nucleotide. A sequence of determined by sequence analysis, with no strong preferences 
operatively linked nucleotides is typically referred to herein observed with respect to the type of base substitution. This 
as a “base sequence” or “nucleotide sequence”, and their allows the introduction of random mutations at any position 
grammatical equivalents, and is represented herein by a in the molecule. 
formula whose left to right orientation is in the conventional 2o Another method useful in introducing defined or random 
direction of 5’-terminus to 3’-terminus, unless otherwise mutations is disclosed in joyce and I ~ ~ ~ ~ ,  ~ ~ ~ l ~ i ~  Acids 
specified. Research 17: 711-722 (1989). This latter method involves 
“Nucleotide analog” generally refers to a purine or pyri- excision of a template (coding) strand of a double-stranded 
midine nucleotide that differs structurally from A, T, G, C, DNA, reconstruction of the template strand with inclusion of 
or U, but is sufficiently similar to substitute for the normal 25 mutagenic oligonucleotides, and subsequent transcription of 
nucleotide in a nucleic acid molecule. As used herein, the the partially-mismatched template. This allows the introduc- 
term “nucleotide analog” encompasses altered bases, differ- tion of defined or random mutations at any position in the 
ent sugars, or a combination of the two. A listing of molecule by including polynucleotides containing known or 
exemplary analogs wherein the base has been altered is random nucleotide sequences at selected positions. 
provided in section C hereinbelow. Enzymatic DNA molecules of the present invention may 
“Oligonucleotide or polynucleotide” generally refers to a be of varying lengths and folding patterns, as appropriate, 
polymer of single- or double-stranded nucleotides. As used depending on the type and function of the molecule. For 
herein, “oligonucleotide” and its grammatical equivalents example, enzymatic DNA molecules may be about 15 to 
will include the full range of nucleic acids. An oligonucle- 35 about 400 or more nucleotides in length, although a length 
otide will typically refer to a nucleic acid molecule com- not exceeding about 250 nucleotides is preferred, to avoid 
prised of a linear strand of ribonucleotides. The exact size limiting the therapeutic usefulness of molecules by making 
will depend on many factors, which in turn depends on the them too large or unwieldy. In various preferred 
ultimate conditions of use, as is well known in the art. embodiments, an enzymatic DNA molecule of the present 
As used herein, the term ‘‘physiologic conditions” is 4o invention is at least about 20 nucleotides in length, and is 
meant to suggest reaction conditions emulating those found Preferably not more than about 100 nucleotides in length. 
in mammalian organisms, particularly humans. While vari- In various therapeutic applications, enzymatic DNA mol- 
ables such as temperature, availability of cations, and pH ecules of the present invention comprise the enzymatically 
ranges may vary as described in greater detail below, “physi- active portions of deoxyribozymes. In various embodiments, 
ologic conditions” generally comprise a temperature of 45 enzymatic DNA molecules of the present invention prefer- 
about 35”-40” C., with 37” C. being particularly preferred, ably comprise not more than about 200 nucleotides. In other 
as well as a pH of about 7.0-8.0, with 7.5 being particularly embodiments, a deoxyribozyme of the present invention 
preferred, and further comprise the availability of cations, comprises not more than about 100 nucleotides, more 
preferably divalent and/or monovalent cations, with a con- preferably, not more than about 50 nucleotides in length. 
centration of about 2-15 mM Mg2+ and 0-1.OM Na+ being so In other applications, enzymatic DNA molecules may 
particularly preferred. “Physiologic conditions”, as used assume configurations similar to those of “hammerhead” 
herein, may optionally include the presence of free nucleo- ribozymes. Such enzymatic DNA molecules are preferably 
side cofactor. As noted previously, preferred conditions are no more than about 100 nucleotides in length, with a length 
described in greater detail below. of about 20-50 nucleotides being particularly preferred. 
B. Enzymatic DNA Molecules In general, if one intends to synthesize molecules for use 
In various embodiments, an enzymatic DNA molecule of as disclosed herein, the larger the enzymatic nucleic acid 
the present invention may combine one or more modifica- molecule is, the more difficult it is to synthesize. Those of 
tions or mutations including additions, deletions, and sub- skill in the art will certainly appreciate these design con- 
stitutions. In alternative embodiments, such mutations or straints. 
modifications may be generated using methods which pro- 60 It is also to be understood that an enzymatic DNA 
duce random or specific mutations or modifications. These molecule of the present invention may comprise enzymati- 
mutations may, for example, change the length of, or alter cally active portions of a deoxyribozyme or may comprise a 
the nucleotide sequence of, a loop, a spacer region or the deoxyribozyme with one or more mutations, e.g., with one 
recognition sequence (or domain). One or more mutations or more base-pair-forming sequences or spacers absent or 
within one catalytically active enzymatic DNA molecule 65 modified, as long as such deletions, additions or modifica- 
may be combined with the mutation(s) within a second tions do not adversely impact the molecule’s ability to 
catalytically active enzymatic DNA molecule to produce a perform as an enzyme. 
The method has been used, for 
30 
5s 
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The recognition domain of an enzymatic DNA molecule optimized ability to cleave nucleic acid substrates, prefer- 
of the present invention typically comprises two nucleotide ably RNA substrates. In preferred embodiments, the 
sequences flanking a catalytic domain, and typically con- enhanced or optimized ability of an enzymatic DNA mol- 
a sequence of at least about 3 to about 30 bases, ecule to cleave RNA substrates shows about a 10- to 
Preferably about 6 to about 15 bases, which are capable of s 109-fold improvement over the uncatalyzed rate. In more 
hybridizing to a complementary sequence of bases within preferred embodiments, an enzymatic DNA molecule of the 
the substrate present invention is able to cleave RNA substrates at a rate 
ecule its high sequence specificity. Modification or mutation that is about 103- to 107-fold improved Over “progenitor,, 
of the recognition site via well-known methods allows one species, In even preferred embodiments, the enhanced 
i o  or optimized ability to cleave RNAsubstrates is expressed as to alter the sequence specificity of an enzymatic nucleic acid molecule. (See, e.g, Joyce et al., Nucleic Acids Research, a lo4- to 106-fold improvement over the progenitor. One 
skilled in the art will appreciate that the enhanced or 17:711-712 (1989.)) Enzymatic nucleic acid molecules of the present invention optimized ability of an enzymatic DNA molecule to cleave include those with altered recognition sites or domains. In nucleic acid substrates may vary depending upon the selec- various embodiments, these altered recognition domains 
IS tion constraints applied during the in vitro evolution proce- confer unique sequence specificities on the enzymatic dure of the invention. nucleic acid molecule including such recognition domains. 
the base sequence at which cleavage will take place. Cleav- and Other enzymatic DNA 
tion domain. This cleavage leaves a 2’, 3’, or 2’, 3’-cyclic 2o 
phosphate group on the substrate cleavage sequence and a 5’ C. Nucleotide Analogs 
hydroxyl on the nucleotide that was originally immediately As noted above, the term ‘‘nucleotide analog” as used 
3’ of the substrate cleavage sequence in the original sub- herein generally refers to a purine or pyrimidine nucleotide 
strate. Cleavage can be redirected to a site of choice by 25 that differs stmcturally from A, T, G, C, or U, but is 
changing the bases present in the recognition sequence sufficiently similar to substitute for the normal nucleotide in 
(internal guide sequence). See Murphy et al., Proc. Natl. a nucleic acid molecule. As used herein, the term “nucle- 
Acad. Sci. USA 86: 9218-9222 (1989). otide analog” encompasses altered bases, different sugars, 
Moreover, it may be useful to add a polyamine to facilitate altered phosphate backbone, or any combination of these 
recognition and binding between the enzymatic DNA mol- 3o alterations. Examples of nucleotide analogs useful according 
ecule and its substrate. Examples of useful polyamines to the present invention include those listed in the following 
include spermidine, putrescine or spermine. A spermidine Table, most of which are found in the approved listing of 
concentration of about 1 mM may be effective in particular modified bases at 37 CFR 51.822 (which is incorporated 
embodiments, while concentrations ranging from about 0.1 herein by reference). 
mM to about 10 mM may also be useful. 
In various alternative embodiments, an enzymatic DNA 
molecule of the present invention has an enhanced or 
optimized ability to cleave nucleic acid substrates, prefer- 
appreciate, the rate of an enzyme-catalyzed reaction varies 4o 
acid giving the enzymatic DNA 
The exact bases present in the recognition domain determine 
age of the substrate nucleic acid occurs within the recogni- 
Various preferred methods Of modifying deoxyribozymes 
present invention are further described in Examples 1-3 
and Of the 
3 s  
TABLE 1 
Nucleotide Analogs 
ably RNA substrates. As those of skill in the art will 
depending upon the substrate and enzyme concentrations ac4c 4-acetylcytidine 
and, in general, levels off at high substrate or enzyme 
concentrations. Taking such effects into account, the kinetics cmnmSs2u 5-carboxymethylaminomethyl-2-thiouridine 
of an enzyme-catalyzed reaction may be described in the 
Abbreviation Description 
chm5u 5- (carboxyhydroxylmethy1)uridine 
cm 
d 
fm 2’-0-methylpseudouridine 
2’-0-methylcytidine 
dihydrouridine 
45 galq fi, D-galactosylqueosine following terms, which define the reaction. 
The enhanced or optimized ability of an enzymatic DNA 
molecule of the present invention to cleave an RNA sub- 
amounts of labeled RNA substrate in the presence of enzy- 
2’-0-methylguanosine 
inosine 
N6-isopentenyladenosine 
;m 
strate may be determined in a cleavage reaction with varying 
matic DNA molecule. The ability to cleave the substrate is so 
generally defined by the catalytic rate (k,,,) divided by the 
Michaelis constant (KM). The symbol k,,, represents the m22g 2,2-dimethylguanosine 
approaches a saturation value. KM represents the substrate m3c 3-methylcytidine 
concentration at which the reaction rate is one-half maximal. 55 msc  5-methylcytidine 
For example, values for KM and k,,, may be determined 
in this invention by experiments in which the substrate 
concentration [SI is in excess over enzymatic DNAmolecule mamSs2u 5-methoxyaminomethyl-2-thiouridine 
concentration [E]. Initial rates of reaction (v,) over a range 
linear phase, generally the first 5% or less of the reaction. 
Data points are fit by a least squares method to a theoretical 
line given by the equation: v=-K~v,i[S])+V,,,. Thus, k,,, 
the substrate concentration [SI. 65 mv uridine-5-oxyacetic acid methylester 
i6a 
m l a  1-methyladenosine 
m l f  1-methylpseudouridine 
mlg 1-methylguanosine 
m l l  1-methylinosine 
m2a 2-methyladenosine 
2-methylguanosine 
maximal velocity of an enzyme reaction when the substrate 
m2g 
m6a 
m7g 7-methylguanosine 
mam5u 5-methylaminomethyluridine 
manq fi, D-mannosylmethyluridine 
mo5u 5-methoxyuridine 
ms2i6a 2-methylthio-N6-isopentenyladenosine 
ms2t6a N-((9-fi-D-ribofuranosyl-2-methylthiopurine-6- 
y1)carbamoyl)threonine 
mt6a N-((9-fi-D-ribofuranosylpurine-6- 
y1)N-methyl-carbamoy1)threonine 
uridine-5-oxyacetic acid (v) 
N6-methyladenosine 
of substrate concentrations are estimated from the initial 60 mcm5s2u 5~methox~carbon~1meth~1uridine 
and KM are determined by the initial rate of reaction, V,, and 
In various alternative embodiments, an enzymatic DNA OSU 
molecule of the present invention has an enhanced or 
5,807,718 
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TABLE 1-continued 
Nucleotide Analogs 
Abbreviation Description 
osyw 
P 
9 
s2c 
s2t 
s2u 
s4u 
t 
t6a 
tm 
um 
YW 
araU 
araT 
X 
wybutoxosine 
pseudouridine 
queosine 
2-thiocytidine 
5-methyl-2-thiouridine 
2-thiouridine 
4-thiouridine 
5-methyluridine 
N-((9-fi-D-ribofuranosylpurine-6- 
y1)carbamoyl)threonine 
2’-0-methyl-5-methyluridine 
Z’-O-methyluridine 
wybutosine 
3-(3-amino-3-carboxypropyl)uridine, (acp 
fi, D-arabinosyl 
fi, D-arabinosyl 
13)U 
Other useful analogs include those described in published 
international application no. WO 92120823 (the disclosures 
of which are incorporated herein by reference), or analogs 
made according to the methods disclosed therein. Analogs 
described in DeMesmaeker, et al., Angew. Chem. Znt. Ed. 
Engl. 33: 226-229 (1994); DeMesmaeker, et al., Synlett: 
733-736 (Oct. 1993); Nielsen, et al., Science 254: 
1497-1500 (1991); and Idziak, et al., Tetrahedron Letters 
34: 5417-5420 (1993) are also useful according to the 
within-disclosed invention and said disclosures are incorpo- 
rated by reference herein. 
D. Methods of Engineering Enzymatic DNA Molecules 
The present invention also contemplates methods of pro- 
ducing nucleic acid molecules having a predetermined activ- 
ity. In one preferred embodiment, the nucleic acid molecule 
is an enzymatic DNA molecule. In another variation, the 
desired activity is a catalytic activity. 
In one embodiment, the present invention contemplates 
methods of synthesizing enzymatic DNA molecules that 
may then be “engineered” to catalyze a specific or prede- 
termined reaction. Methods of preparing enzymatic DNA 
molecules are described herein; see, e.g., Examples 1-3 
hereinbelow. In other embodiments, an enzymatic DNA 
molecule of the present invention may be engineered to bind 
small molecules or ligands, such as adenosine triphosphate 
(ATP). (See, e.g., Sassanfar, et al., Nature 364: 55Ck553 
(1993).) 
In another embodiment, the present invention contem- 
plates that a population of enzymatic DNA molecules may 
be subjected to mutagenizing conditions to produce a 
diverse population of mutant enzymatic DNA molecules 
(which may alternatively be called “deoxyribozymes”). 
Thereafter, enzymatic DNA molecules having desired char- 
acteristics are selected and/or separated from the population 
and are subsequently amplified. 
Alternatively, mutations may be introduced in the enzy- 
matic DNA molecule by altering the length of the recogni- 
tion domains of the enzymatic DNA molecule. The recog- 
nition domains of the enzymatic DNA molecule associate 
with a complementary sequence of bases within a substrate 
nucleic acid sequence. Methods of altering the length of the 
recognition domains are known in the art and include PCR, 
for example; useful techniques are described further in the 
Examples below. 
Alteration of the length of the recognition domains of an 
enzymatic DNAmolecule may have a desirable effect on the 
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binding specificity of the enzymatic DNA molecule. For 
example, an increase in the length of the recognition 
domains may increase binding specificity between the enzy- 
matic DNA molecule and the complementary base 
sequences of an oligonucleotide in a substrate, or may 
enhance recognition of a particular sequence in a hybrid 
substrate. In addition, an increase in the length of the 
recognition domains may also increase the affinity with 
which it binds to substrate. In various embodiments, these 
altered recognition domains in the enzymatic DNAmolecule 
confer increased binding specificity and affinity between the 
enzymatic DNA molecule and its substrate. 
It has recently been noted that certain oligonucleotides are 
able to recognize and bind molecules other than oligonucle- 
otides with complementary sequences. These oligonucle- 
otides are often given the name “aptamers”. For example, 
Ellington and Szostak describe RNA molecules that are able 
to bind a variety of organic dyes (Nature 346: 818-822 
(1990)), while Bock, et al. describe ssDNA molecules that 
bind human thrombin (Nature 355: 564-566 (1992)). 
Similarly, Jellinek, et al. describe RNA ligands to basic 
fibroblast growth factor (PNAS USA 90: 11227-11231 
(1993)). Thus, it is further contemplated herein that the 
catalytically active DNA enzymes of the present invention 
may be engineered according to the within-described meth- 
ods to display a variety of capabilities associated with 
apt amers . 
One of skill in the art should thus appreciate that the 
enzymatic DNA molecules of this invention can be altered 
at any nucleotide sequence, such as the recognition domains, 
by various methods disclosed herein, including PCR and 
3SR. For example, additional nucleotides can be added to 
the 5’ end of the enzymatic DNA molecule by including 
additional nucleotides in the primers. 
Enzymatic DNA molecules of the present invention may 
also be prepared or engineered in a more non-random 
fashion via use of methods such as site-directed mutagen- 
esis. For example, site-directed mutagenesis may be carried 
out essentially as described in Morinaga, et al., Biotechnol- 
ogy 2: 636 (1984), modified as described herein, for appli- 
cation to deoxyribozymes. Useful methods of engineering 
enzymatic DNA molecules are further described in the 
Examples below. 
In one disclosed embodiment, an enzymatic DNA mol- 
ecule of the present invention comprises a conserved core 
flanked by two substrate binding (or recognition) domains or 
sequences that interact with the substrate through base- 
pairing interactions. In various embodiments, the conserved 
core comprises one or more conserved domains or 
sequences. In another variation, an enzymatic DNA mol- 
ecule further comprises a “spacer” region (or sequence) 
between the regions (or sequences) involved in base pairing. 
In still another variation, the conserved core is “interrupted” 
at various intervals by one or more less-conserved variable 
or “spacer” nucleotides. 
In various embodiments, the population of enzymatic 
DNA molecules is made up of at least 2 different types of 
deoxyribozyme molecules. For example, in one variation, 
the molecules have differing sequences. In another variation, 
the deoxyribozymes are nucleic acid molecules having a 
nucleic acid sequence defining a recognition domain that is 
contiguous or adjacent to the 5’-terminus of the nucleotide 
sequence. In various alternative embodiments, enzymatic 
DNA molecules of the present invention may further com- 
prise one or more spacer regions located 3’-terminal to the 
recognition domains, one or more loops located 3’-terminal 
5,807,718 
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to the recognition domains and/or spacer regions. In other predetermined activity becomes labelled in some fashion by 
variations, a deoxyribozyme of the present invention may virtue of the activity. For example, the predetermined activ- 
comprise one or more regions which are capable of hybrid- ity may be an enzymatic DNA molecule activity whereby 
izing to other regions of the same molecule. Other charac- the activity of the mutant enzymatic nucleic acid upon its 
teristics of enzymatic DNA molecules produced according 5 substrate causes the mutant enzymatic nucleic acid to 
to the presently-disclosed methods are described elsewhere become covalently linked to it. The mutant enzymatic 
herein. nucleic acid is then selected by virtue of the covalent 
In other embodiments, mutagenizing conditions include linkage. 
conditions that introduce either defined or random nucle- In other embodiments, selecting a mutant enzymatic 
otide substitutions within an enzymatic DNA molecule. nucleic acid having a predetermined activity includes ampli- 
Examples of typical mutagenizing conditions include con- fication of the mutant enzymatic nucleic acid (see, e.g., 
ditions disclosed in other parts of this specification and the Joyce, Gene 82: 83-87 (1989); Beaudry and Joyce, Science 
methods described by Joyce et al., Nucl. Acids Res. 17: 257: 635-41 (1992)). Other methods of selecting an enzy- 
711-722 (1989); Joyce, Gene 82: 83-87(1989); and Beaudry matic nucleic acid molecule having a predetermined char- 
and Joyce, Science 257: 635-41 (1992). acteristic or activity are described in the Examples section. 
In still other embodiments, a diverse population of mutant E. Compositions 
enzymatic nucleic acid molecules of the present invention is The invention also contemplates compositions containing 
one that contains at least 2 nucleic acid molecules that do not one or more types or populations of enzymatic DNA mol- 
have the exact Same nucleotide sequence. In other ecules of the present invention; e.g., different types or 
variations, from such a diverse population, an enzymatic 2o populations may recognize and cleave different nucleotide 
DNA molecule or other enzymatic nucleic acid having a sequences. Compositions may further include a ribonucleic 
predetermined activity is then selected on the basis of its acid-containing substrate. Compositions according to the 
ability to perform the predetermined activity. In various present invention may further comprise lead ion, magnesium 
embodiments, the predetermined activity comprises, without ion, or other divalent or monovalent cations, as discussed 
limitation, enhanced catalytic activity, decreased KM, 25 herein. 
enhanced substrate binding ability, altered substrate preferably, the enzymatic DNA molecule is present at a 
specificity, and the like. concentration of about 0.05 pM to about 2pM. Typically, the 
Other parameters which may be considered aspects of enzymatic DNA molecule is present at a concentration ratio 
enzyme performance include catalytic activity or capacity, of enzymatic DNA molecule to substrate of from about 1:5 
substrate binding ability, enzyme turnover rate, enzyme 3o to about 1:50. More preferably, the enzymatic DNA mol- 
sensitivity to feedback mechanisms, and the like. In certain ecule is present in the composition at a concentration of 
aspects, substrate specificity may be considered an aspect of about 0.1 pM to about 1 pM. Even more preferably, com- 
enzyme performance, particularly in situations in which an positions contain the enzymatic DNA molecule at a concen- 
enzyme is able to recognize and bind two or more competing tration of about 0.1 pM to about 0.5 pM. Preferably, the 
substrates, each of which affects the enzymes’ performance 35 substrate is present in the composition at a concentration of 
with respect to the other substrate(s). about 0.5 pM to about 1000 pM. One skilled in the art will 
Substrate specificity, as used herein, may refer to the understand that there are many sources of nucleic acid- 
specificity of an enzymatic nucleic acid molecule as containing substrates including naturally-occurring and syn- 
described herein for a particular substrate, such as one thetic sources. Sources of suitable substrates include, with- 
comprising ribonucleotides only, deoxyribonucleotides only, 4o out limitation, a variety of viral and retroviral agents, 
or a composite of both. Substrate molecules may also including HIV-1, HIV-2, HTLV-I, and HTLV-11. 
contain nucleotide analogs. In various embodiments, an Other suitable substrates include, without limitation, viral 
enzymatic nucleic acid molecule of the present invention and retroviral agents including those comprising or pro- 
may preferentially bind to a particular region of a hybrid or duced by picornaviruses, hepadnaviridae (e.g., HBV HCV), 
non-hybrid substrate. 45 papillomaviruses (e.g., HPV), gammaherpesvirinae (e.g., 
The term or parameter identified herein as “substrate EBV), lymphocryptoviruses, leukemia viruses (e.g., HTLV-I 
specificity” may also include sequence specificity; i.e., an and -11), flaviviruses, togaviruses, herpesviruses (including 
enzymatic nucleic acid molecule of the present invention alphaherpesviruses and betaherpesviruses), cytomegalovi- 
may “recognize” and bind to a nucleic acid substrate having ruses (CMV), influenza viruses, and viruses and retroviruses 
a particular nucleic acid sequence. For example, if the so contributing to immunodeficiency diseases and syndromes 
substrate recognition domains of an enzymatic nucleic acid (e.g., HIV-1 and -2). In addition, suitable substrates include 
molecule of the present invention will only bind to substrate viral and retroviral agents which infect non-human primates, 
molecules having a series of one or two ribonucleotides including, without limitation, the simian and feline immu- 
(e.g., rA) in a row, then the enzymatic nucleic acid molecule nodeficiency viruses and bovine leukemia viruses. 
will tend not to recognize or bind nucleic acid substrate 5s Magnesium ion, lead ion, or another suitable monovalent 
molecules lacking such a sequence. or divalent cation, as described previously, may also be 
With regard to the selection process, in various present in the composition, at a concentration of about 
embodiments, selecting includes any means of physically 1-100 mM. More preferably, the preselected ion is present 
separating the mutant enzymatic nucleic acids having a in the composition at a concentration of about 2 mM to about 
predetermined activity from the diverse population of 60 50 mM, with a concentration of about 5 mM being particu- 
mutant enzymatic nucleic acids. Often, selecting comprises larly preferred. One skilled in the art will understand that the 
separation by size, by the presence of a catalytic activity, or ion concentration is only constrained by the limits of solu- 
by hybridizing the mutant nucleic acid to another nucleic bility of it source (e.g. magnesium) in aqueous solution and 
acid, to a peptide, or some other molecule that is either in a desire to have the enzymatic DNAmolecule present in the 
solution or attached to a solid matrix. 
In various embodiments, the predetermined activity is The invention also contemplates compositions containing 
such that the mutant enzymatic nucleic acid having the an enzymatic DNA molecule of the present invention, 
15 
65 same composition in an active conformation. 
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hybrid deoxyribonucleotide-ribonucleotide molecules, and the substrate cleavage sequence so that an enzymatic nucleic 
magnesium or lead ion in concentrations as described here- acid molecule of the present invention can hybridize to the 
inabove. As noted previously, other monovalent or divalent substrate cleavage sequence by virtue of the enzyme’s 
ions (e.g., Ca”) may be used in place of magnesium. recognition sequence. 
Also contemplated by the present invention are compo- 5 A nucleic acid substrate that can be cleaved by a method 
sitions containing an enzymatic DNA molecule of the of this invention may be chemically synthesized or enzy- 
present invention, nucleic acid-containing substrate (e.g. matically produced, or it may be isolated from various 
RNA), and a preselected ion at a concentration of greater sources such as phages, viruses, prokaryotic cells, or eukary- 
than about 1 millimolar, wherein said substrate is greater in otic cells, including animal cells, plant cells, eukaryotic 
length than the recognition domains present on the enzy- 10 cells, yeast cells and bacterial cells. Chemically synthesized 
matic DNA molecule. single-stranded nucleic acids are commercially available 
DNA molecule-substrate complex, wherein base pairing Genetics (Huntsville, Ala.). 
between an enzymatic DNA molecule and its substrate is RNA substrates may also be synthesized using an Applied 
contiguous. In another embodiment, base pairing between an Biosystems (Foster City, Calif.) oligonucleotide synthesizer 
enzymatic DNA molecule and its substrate is interrupted by according to the manufacture’s instructions. Single-stranded 
one or more noncomplementary pairs. phages are also sources of nucleic acid substrates. (See, e.g., 
In a variety of alternative embodiments, a composition of Messing et al., PNAS USA 74: 3642-3646 (1977), and 
the present invention may further comprise a monovalent Yanisch-Perron et al., Gene 33: 103-119 (1985).) Bacterial 
cation, a divalent cation, both, or neither. 2o cells containing single-stranded phages would also be a 
another variation, an enzymatic DNA molecule of the ready source of suitable single-stranded nucleic acid. 
present invention is capable of functioning efficiently in the Single-stranded RNA cleavable by a method of the 
presence or absence of a divalent cation. In one variation, a present invention could be provided by any of the RNA 
divalent cation is present and comprises Pb2+, Mg2+, Zn”, viruses such as the picornaviruses,  togaviruses,  
or Ca”. Alternatively, an enzymatic DNA molecule of the 25 orthomyxoviruses, paramyxoviruses, rhabdoviruses, 
present invention is capable of functioning efficiently in the coronaviruses, arenaviruses or retroviruses. As noted 
presence or absence of divalent cations. It is anticipated that previously, a wide variety of prokaryotic and eukaryotic 
cation concentrations similar to those described herein for cells may also be excellent sources of suitable nucleic acid 
substrates. Pb”wil1 be useful as disclosed herein. 
Optionally, monovalent cations may also be present in The methods of this invention may be used on single- 
addition to, or as “alternatives” for, divalent cations. For stranded nucleic acids or single-stranded portions of looped 
example, monovalent cations such as sodium (Na’) or or double-stranded nucleic acids that are present inside a 
potassium (K+) may be present, either as dissociated ions or cell, including eucaryotic, procaryotic, plant, animal, yeast 
in the form of dissociable compounds such as NaCl or KC1. 35 or bacterial cells. Under these conditions an enzymatic 
In one embodiment, the concentration of monovalent nucleic acid molecule (e.g., an enzymatic DNA molecule or 
cation present in the composition ranges from e1.OM. In deoxyribozyme) of the present invention could act as an 
another embodiment, a monovalent cation is present in a anti-viral agent or a regulator of gene expression. Examples 
concentration ranging from about 0-200 mM. In other of such uses of enzymatic DNA molecules of the present 
embodiments, monovalent cations are present in a concen- 4o invention are described further hereinbelow. 
tration ranging from about 1-100 mM. Alternatively, the In the majority of methods of the present invention, 
concentration of monovalent cations ranges from about 2 cleavage of single-stranded nucleic acids occurs at the 
mM-50 mM. In still other embodiments, the concentration 3’-terminus of a predetermined base sequence. This prede- 
ranges from about 2 mM-25 mM. termined base sequence or substrate cleavage sequence 
F. Methods of Using Enzymatic DNA Molecules 45 typically contains from 1 to about 10 nucleotides. In other 
The methods of using enzymatic DNA molecules as preferred embodiments, an enzymatic DNA molecule of the 
disclosed herein are legion, As discussed previously, mol- present invention is able to recognize nucleotides either 
ecules capable of cleaving the bonds linking neighboring upstream, Or upstream and downstream of the cleavage site. 
nucleic acids (e.g., phosphoester bonds) have numerous uses In various embodiments, an enzymatic DNA molecule is 
encompassing a wide variety of applications. For example, 50 able to recognize about 2-10 nucleotides upstream of the 
enzymatic DNA molecules having the within-disclosed cleavage site; in other embodiments, an enzymatic DNA 
es, structures, and/or functions are useful in phar- molecule is able to recognize about 2-10 nucleotides 
maceutical and medical products (e,g, ,  for wound upstream and about 2-10 nucleotides downstream of the 
debridement, clot dissolution, etc.), as well as in household cleavage site. Other Preferred ~ ~ b o d i m e n t s  contemplate an 
items (e.g., detergents, dental hygiene products, meat 5s enzymatic DNA molecule that is capable of recognizing a 
compounds, compositions and methods is also contemplated with a length UP to about 20 nucleotides being even more 
and well within the scope of the present invention. preferred. 
The present invention also describes useful methods for The within-disclosed methods allow cleavage at any 
cleaving any single-stranded, looped, partially or fully 60 nucleotide sequence by altering the nucleotide sequence of 
In one variation, a composition comprises an enzymatic from many sources including, without limitation, Research 
30 
tenderizers), Industrial utility of the within-disclosed nucleotide sequence UP to about 30 nucleotides in length, 
double-stranded nucleic acid; the majority of these methods the recognition domains of the enzymatic DNA molecule. 
employ the novel enzymatically active nucleic acid mol- This allows cleavage of single-stranded nucleic acid in the 
ecules of the present invention. In various embodiments, the absence of a restriction endonuclease site at that position. 
single-stranded nucleic acid segment or portion of the sub- An enzymatic DNA molecule of the present invention 
strate (or the entire substrate itself) comprises DNA, modi- 65 may be separated from the remainder of the single-stranded 
fied DNA, RNA, modified RNA, or composites thereof. The nucleic acid substrate by site-specific hydrolysis at the 
nucleic acid substrate must only be single-stranded at or near appropriate cleavage site. Separation of the enzymatic DNA 
19 
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molecule from the substrate allows the enzymatic DNA 
molecule to carry out another cleavage reaction. 
Generally, the nucleic acid substrate is treated under 
appropriate nucleic acid cleaving conditions-preferably, 
physiologic conditions-with an effective amount of an 
enzymatic DNA molecule of the present invention. If the 
nucleic acid substrate comprises DNA, cleaving conditions 
may include the presence of a divalent cation at a concen- 
tration of about 2-10 mM. 
An effective amount of an enzymatic DNAmolecule is the 
amount required to cleave a predetermined base sequence 
present within the single-stranded RNA. Preferably, the 
enzymatic DNA molecule is present at a molar ratio of DNA 
molecule to substrate cleavage sites of 1 to 20. This ratio 
may vary depending on the length of treating and efficiency 
of the particular enzymatic DNA molecule under the par- 
ticular RNA cleavage conditions employed. 
Treating typically involves admixing, in aqueous solution, 
the RNA-containing substrate and the enzyme to form a 
cleavage admixture, and then maintaining the admixture 
thus formed under RNA cleaving conditions for a time 
period sufficient for the enzymatic DNA molecule to cleave 
the RNA substrate at any of the predetermined nucleotide 
sequences present in the RNA. In various embodiments, a 
source of ions is also provided-i.e. monovalent or divalent 
cations, or both. 
In one embodiment of the present invention, the amount 
of time necessary for the enzymatic DNAmolecule to cleave 
the single-stranded nucleic acid has been predetermined. 
The amount of time is from about 1 minute to about 24 hours 
and will vary depending upon the concentration of the 
reactants, and the temperature of the reaction. Usually, this 
time period is from about 10 minutes to about 2 hours such 
that the enzymatic DNA molecule cleaves the single- 
stranded nucleic acid at any of the predetermined nucleotide 
sequences present. 
The invention further contemplates that the nucleic acid 
cleaving conditions include the presence of a source of 
divalent cations (e.g., PbOAc) at a concentration of about 
2-100 mM. Typically, the nucleic acid cleaving conditions 
include divalent cation at a concentration of about 2 mM to 
about 10 mM, with a concentration of about 5 mM being 
particularly preferred. 
The optimal cationic concentration to include in the 
nucleic acid cleaving conditions can be easily determined by 
determining the amount of single-stranded nucleic acid 
cleaved at a given cation concentration. One skilled in the art 
will understand that the optimal concentration may vary 
depending on the particular enzymatic DNA molecule 
employed. 
The present invention further contemplates that the 
nucleic acid cleaving conditions are at from about pH 6.0 to 
about pH 9.0. In one preferred embodiment, the pH ranges 
from about pH 6.5 to pH 8.0. In another preferred 
embodiment, the pH emulates physiological conditions, i.e., 
the pH is about 7.0-7.8, with a pH of about 7.5 being 
particularly preferred. 
One skilled in the art will appreciate that the methods of 
the present invention will work over a wide pH range so long 
as the pH used for nucleic acid cleaving is such that the 
enzymatic DNA molecule is able to remain in an active 
conformation. An enzymatic DNA molecule in an active 
conformation is easily detected by its ability to cleave 
single-stranded nucleic acid at a predetermined nucleotide 
sequence. 
In various embodiments, the nucleic acid cleaving con- 
ditions also include a variety of temperature ranges; as noted 
previously, temperature ranges consistent with physiological 
conditions are especially preferred. In one embodiment, the 
temperature ranges from about 15" C. to about 60" C. In 
another variation, the nucleic acid cleaving conditions are 
s from about 30" C. to about 56" C. The temperature of the 
nucleic acid cleaving conditions are constrained only by the 
desired cleavage rate and the stability of that particular 
enzymatic DNA molecule at that particular temperature. In 
yet another variation, nucleic acid cleavage conditions 
i o  include a temperature from about 35" C. to about 50" C. In 
a preferred embodiment, nucleic acid cleavage conditions 
comprise a temperature range of about 37" C. to about 42" 
C. 
In various methods, the present invention contemplates 
15 nucleic acid cleaving conditions including the presence of a 
polyamine. Polyamines useful for practicing the present 
invention include spermidine, putrescine, spermine and the 
like. In one variation, the polyamine is spermidine and it is 
present at a concentration of about 0.01 mM to about 10 
20 mM. In another variation, the polyamine is present at a 
concentration of about 1 mM to about 10 mM. Nucleic acid 
cleavage conditions may also include the presence of 
polyamine at a concentration of about 2 mM to about 5 mM. 
In various preferred embodiments, the polyamine is sper- 
25 midine. 
G. Vectors 
The present invention also features expression vectors 
including a nucleic acid segment encoding an enzymatic 
DNA molecule of the present invention situated within the 
30 vector, preferably in a manner which allows expression of 
that enzymatic DNA molecule within a target cell (e.g., a 
plant or animal cell). 
Thus, in general, a vector according to the present inven- 
35 tion preferably includes a plasmid, cosmid, phagemid, virus, 
or phage vector. Preferably, suitable vectors comprise 
single-stranded DNA (ssDNA)-e.g., circular phagemid 
ssDNA. It should also be appreciated that useful vectors 
according to the present invention need not be circular. 
In one variation, nucleotide sequences flanking each of 
the additional enzymatic DNA molecule-encoding 
sequences are preferably provided, which sequences may be 
recognized by the first enzymatic DNA molecule. The 
intervening or flanking sequences preferably comprise at 
45 least 1 nucleotide; more preferably, intervening or flanking 
sequences are about 2-20 nucleotides in length, with 
sequences of about 5-10 nucleotides in length being par- 
ticularly preferred. 
The addition of polynucleotide tails may also be useful to 
50 protect the 3' end of an enzymatic DNAmolecule according 
to the present invention. These may be provided by attaching 
a polymeric sequence by employing the enzyme terminal 
transferase. 
A vector according to the present invention includes two 
ss or more enzymatic DNA molecules. In one embodiment, a 
first enzymatic DNA molecule has intramolecular cleaving 
activity and is able to recognize and cleave nucleotide 
sequences to release other enzymatic DNA sequences; i.e., 
it is able to function to "release" other enzymatic DNA 
60 molecules from the vector. For example, a vector is prefer- 
ably constructed so that when the first enzymatic DNA 
molecule is expressed, that first molecule is able to cleave 
nucleotide sequences flanking additional nucleotide 
sequences encoding a second enzymatic DNA molecule, a 
65 third enzymatic DNA molecule, and so forth. Presuming 
said first enzymatic DNA molecule (i.e., the "releasing" 
molecule) is able to cleave oligonucleotide sequences 
4o 
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intramolecularly, the additional (e.g. second, third, and so of these processes can be realized in vitro (Joyce, Gene 82: 
on) enzymatic DNA molecules (i.e., the “released” 83 (1989)). A gene can be mutagenized by chemical 
molecules) need not possess characteristics identical to the modification, incorporation of randomized mutagenic 
“releasing” molecule. Indeed, in various preferred oligodeoxynucleotides, or inaccurate copying by a poly- 
embodiments, the “released” (i.e. second, third, etc.) enzy- s merase. (See, e.g., Cadwell and Joyce, in PCR Methods and 
matic DNA molecule has amide bond-cleaving activity, Applications 2: 28-33 (1992); Cadwell and Joyce, PCR 
while the first (“releasing”) enzymatic DNA molecule has Methods and Applications 3 (Suppl.): S136-S140 (1994); 
nuclease activity. Chu, et al., vlrology 98: 168 (1979); Shortle, et al., Meth. 
Alternatively, the first enzymatic DNA molecule may be Enqmol. 100: 457 (1983); Myers, et al.9 & ~ U K X  229: 242 
encoded on a separate vector from the second enzymatic 10 (1985); Matteucci, et al., Nucleic Acids Res. 11: 3113 
DNA molecule(s) and may have intermolecular cleaving (1983); w e b  et al.9 Gene 34: 315 (1985); McNeil, et al.9 
activity. As noted herein, the first enzymatic DNAmolecule Mol. Cell. Bid.  5: 3545 (1985); Hutchison, et al.,PNAS USA 
can be a self-cleaving enzymatic DNA molecule (e.g., a 83: 710 (1986); DerbYshk et al.9 46: 145 (1986); 
deoxyribozyme), and the second enzymatic DNA molecule ZakoUr, et al., Nature 295: 708 (1982); Lehtovaara, et al., 
may be any desired type of enzymatic DNA molecule (e.g., 15 protein En&’. 2: 63 (198% Leung, et al.9 Technique 1: 11 
a deoxyribozyme). When a vector is caused to express RNA (1989); ZhOU, et al.9 NuCl. Acids Res. 19: 6052 (19911.1 
from these nucleic acid sequences, that RNA has the ability The gene product can be selected, for example, by its 
under appropriate conditions to cleave each of the flanking ability to bind a ligand or to carry out a chemical reaction. 
regions, thereby releasing one or more copies of the second (See, e.g., Joyce, Id. (1989); Robertson and Joyce, Nature 
enzymatic DNA molecule. If desired, several different sec- 20 344: 467 (1990); Tuerk, et al., Science 249: 505 (1990).) The 
ond enzymatic DNA molecules can be placed in the same gene that corresponds to the selected gene product can be 
cell or carrier to produce different deoxyribozymes. amplified by a reciprocal primer method, such as the poly- 
Methods of isolating and purifying enzymatic DNA mol- merase chain reaction (PCR). (See, e.g., Saiki, et al., Science 
ecules of the present invention are also contemplated. In 230: 1350-54 (1985); Saiki, et al., Science 239: 487-491 
addition to the methods described herein, various purifica- 25 (19881.1 
tion methods (e.g. those using HPLC) and chromatographic Alternatively, nucleic acid amplification may be carried 
isolation techniques are available in the art. See, e.g., the out using self-sustained sequence replication (3SR). (See, 
methods described in published international application no. e.g., Guatelli, et al., PNAS USA 87: 1874 (1990), the 
WO 93123569, the disclosures of which are incorporated disclosures of which are incorporated by reference herein.) 
herein by reference. 30 According to the 3SR method, target nucleic acid sequences 
It should also be understood that various combinations of may be amplified (replicated) exponentially in vitro under 
the embodiments described herein are included within the isothermal conditions by using three enzymatic activities 
scope of the present invention, Other features and advan- essential to retroviral replication: (1) reverse transcriptase, 
tages of the present invention will be apparent from the (2) RNase H, and (3) a DNA-dePendent RNA Polymerase. 
descriptions hereinabove, from the Examples to follow, and 35 BY mimicking the retroviral strategy of RNArePlication by 
from the claims. means of cDNA intermediates, this reaction accumulates 
cDNA and RNA copies of the original target. 
In summary, if one is contemplating the evolution of a 
The following examples illustrate, but do not limit, the 40 Population of enzymatic DNA molecules, a continuous 
series of reverse transcription and transcription reactions 
replicates an RNA target sequence by means of cDNA 
intermediates. The crucial elements of this design are (a) the 
oligonucleotide primers both specify the target and contain 
45 5’ extensions encoding the T7 RNApolymerase binding site, 
so that the resultant cDNAs are competent transcription 
In vitro selection and in vitro evolution techniques allow templates; (b) CDNAsYnthesis can Proceed to completion of 
new catalysts to be isolated without a priori knowledge of both strands due to the degradation of template RNAin the 
their composition or structure. Such methods have been used intermediate RNA-DNA RNase and the 
to obtain RNA enzymes with novel catalytic properties. For 50 
example, ribozymes that undergo autolytic cleavage with Plates for subsequent steps, enabling exponential replica- 
lead cation have been derived from a randomized pool of tion. 
tRNAPhe molecules (Pan and Uhlenbeck, Biochemistry 31: If one is evolving enzymatic DNA molecules, various 
3887-3895 (1992)). Group I ribozyme variants have been critical elements of this design are somewhat different, as 
isolated that can cleave DNA (Beaudry and Joyce, Science 55 disclosed in these Examples. For instance, (1) the oligo- 
257: 635-641 (1992)) or that have altered metal dependence nucleotide primers specify the target and are preferably 
(Lehman and Joyce, Nature 361: 182-185 (1993)). Starting “marked” or labeled in some fashion-e.g., via 
with a pool of random RNAsequences, molecules have been biotinylation-so the resultant competent template strands 
obtained that catalyze a polymerase-like reaction (Bartel and are easily identified; and (2) the in vitro selection procedure 
Szostak, Science 261: 1411-1418 (1993)). In the present 60 used preferably depends upon the identification of the most 
example, refinement of specific catalytic properties of an favorable release mechanism. 
during an in vitro evolution procedure is described. is the need to integrate mutation and amplification, both of 
Darwinian evolution requires the repeated operation of which are genotype-related, with selection, which is 
three processes: (a) introduction of genetic variation; (b) 65 phenotype-related. In the case of nucleic acid enzymes, for 
selection of individuals on the basis of some fitness crite- which genotype and phenotype are embodied in the same 
rion; and (c) amplification of the selected individuals. Each molecule, the task is simplified. 
EXAMPLES 
present invention. 
Example 1 
In Vitro Evolution of Enzymatic DNA Molecules: 
An Overview 
Products (cDNA and RNA) can function as 
evolved enzyme via alteration of the selection constraints A major obstacle to realizing Darwinian evolution in vitro 
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A. Design of Enzymatic DNA Molecules phosphoester, initially presented within a short leader 
It is well known that single-stranded DNA can assume sequence attached to the 5’ end of the DNA, and ultimately 
interesting tertiary structures. The structure of a “tDNA”, for located within a separate molecule that could be cleaved in 
example, closely resembles that of the corresponding tRNA. an intermolecular fashion with rapid catalytic turnover. 
(See Paquette, et al.,Eur: J .  Biochem. 189: 259-265 (1990).) s These goals were successfully achieved, as described further 
Furthermore, it has been possible to replace as many as 31 below. 
of 35 ribonucleotides within a hammerhead ribozyme, while No assumptions were made as to how the DNA would 
retaining at least some catalytic activity. (See Perreault, et interact with the target phosphoester and surrounding nucle- 
al., Nature 344: 565-567 (1990); Williams, et al., Proc. Natl. otides. Beginning with a pool of approximately l O I 4  random 
Acad. Sci. USA 89: 918-921 (1992); Yang, et al., Biochem- i o  50mer sequences, in vitro selection was allowed to run its 
istry 31: 5005-5009 (1992). course. After five rounds of selection carried out over four 
In vitro selection techniques have been applied to large days, the population as a whole had attained the ability to 
populations of random-sequence DNAs, leading to the cleave the target phosphoester in the presence of 1 mM 
recovery of specific DNA “aptamers” that bind a target Pb2+at a rate of about 0.2 min-l. This is an approximately 
ligand with high affinity (Bock, et al., Nature 355: 564-566 is 105-fold increase compared to the spontaneous rate of 
(1992); Ellington & Szostak, Nature 355: 85&852 (1992); cleavage under the same reaction conditions. 
Wyatt & Ecker, PNAS USA 91: 1356-1360 (1994)). Individuals were isolated from the population, sequenced, 
Recently, two groups carried out the first NMR structural and assayed for catalytic activity. Based on this information, 
determination of an aptamer, a 15mer DNA that forms a the reaction was converted to an intermolecular format and 
G-quartet structure and binds the protein thrombin with high 20 then simplified to allow site-specific cleavage of a 19mer 
affinity (Wang, et al., Biochemistry 32: 1899-1904 (1993); substrate by a 38mer DNA enzyme, in a reaction that 
Macaya, et al., PNAS USA 90: 3745-3749 (1993)). These proceeds with a turnover rate of 1 min-l at 23” C. and pH 
findings were corroborated by an X-ray crystallographic 7.0 in the presence of 1 mM PbOAc. 
analysis (Padmanabhan, et al., J .  Biol. Chem. 268: B. In Vitro Selection Scheme 
17651-17654 (1993)). zs A starting pool of approximately l O I 4  single-stranded 
The ability to bind a substrate molecule with high affinity DNA molecules was generated, all of which contain a 5’ 
and specificity is a prerequisite of a good enzyme. In biotin moiety, followed successively by a fixed domain that 
addition, an enzyme must make use of well-positioned includes a single ribonucleotide, a potential catalytic domain 
functional groups, either within itself or a cofactor, to comprised of 50 random deoxyribonucleotides, and a second 
promote a particular chemical transformation. Furthermore, 30 fixed domain that lay at the 3’ terminus (FIG. 1). 
the enzyme must remain unchanged over the course of the The pool was constructed by a nested PCR (polymerase 
reaction and be capable of operating with catalytic turnover. chain reaction) technique, beginning with synthetic DNA 
Some would add the requirement that it be an informational that contained 50 random nucleotides flanked by primer 
macromolecule, comprised of subunits whose specific order- binding sites. The nested PCR primer was a 5’-biotinylated 
ing is responsible for catalytic activity. While these criteria 3s synthetic oligodeoxynucleotide with a 3’-terminal adenosine 
are open to debate on both semantic and chemical grounds, ribonucleotide. Ribonucleotide-terminated oligonucleotides 
they serve to distinguish phenomena of chemical rate efficiently prime template-directed elongation in the context 
enhancement that range from simple solvent effects to of the PCR (L. E. Orgel, personal communication), in this 
biological enzymes operating at the limit of substrate dif- case giving rise to an extension product that contains a single 
fusion (Albery & Knowles, Biochemistry 15: 5631-5640 40 embedded ribonucleotide. 
(1976)). FIG. 1 illustrates a selective amplification scheme for 
As described in greater detail hereinbelow, we sought to isolation of DNAs that cleave a target RNA phosphoester. 
develop a general method for rapidly obtaining DNA cata- Double-stranded DNA containing a stretch of 50 random 
lysts and DNA enzymes, starting from random sequences. nucleotides is amplified via PCR, employing a 
As an initial target, we chose a reaction that we felt was well 4s 5’-biotinylated DNA primer (e.g., primer 3-3a or 3b) 
within the capability of D N A  the hydrolytic cleavage of an terminated at the 3’ end by an adenosine ribonucleotide 
RNA phosphodiester, assisted by a divalent metal cofactor. (represented by the symbol “N’  or “rA”, wherein both N and 
This is the same reaction that is carried out by a variety of rA represent an adenosine ribonucleotide). This primer is 
naturally-occurring RNA enzymes, including the hammer- extended by Taq polymerase to yield a DNA product that 
head and hairpin motifs. (See, e.g., Forster A. C. & Symons SO contains a single embedded ribonucleotide. The resulting 
R. H., Cell 49: 211-220 (1987); Uhlenbeck, Nature 328: double-stranded DNA is immobilized on a streptavidin 
596-600 (1987); Hampel & Tritz, Biochemistry 28: matrix and the unbiotinylated DNA strand is removed by 
4929-4933 (1989)). washing with 0.2N NaOH. After re-equilibrating the column 
It has recently been shown that, beginning with a ran- with a buffered solution, the column is washed with the same 
domized library of tRNA molecules, one can obtain ss solution with added 1 mM PbOAc. DNAs that undergo 
ribozymes that have Pb2+-dependent, site-specific RNA Pb2+-dependent self-cleavage are released from the column, 
phosphoesterase activity at neutral pH (Pan & Uhlenbeck, collected in the eluant, and amplified by PCR. The PCR 
Biochemistry 31: 3887-3895 (1992); Pan & Uhlenbeck, products are then used to initiate the next round of selective 
Nature 358: 560-563 (1992)). This is analogous to the amplification. 
fortuitous self-cleavage reaction of yeast tRNAPhe 60 The PCR products were passed over a streptavidin affinity 
(Dirheimer & Werner, Biochimie 54: 127-144 (1972)), matrix, resulting in noncovalent attachment of the 
which depends on specific coordination of a Pb2+ion at a 5’-biotinylated strand of the duplex DNA. The nonbiotiny- 
defined site within the tRNA. (See Rubin & Sundaralingam, lated strand was removed by brief washing with 0.2N 
J .  Biomol. Struct. Dyn. 1: 639-646 (1983); Brown, et al., NaOH, and the bound strand was equilibrated in a buffer 
Biochemistry 24: 4785-4801 (1985).) As disclosed herein, 65 containing 0.5M NaC1, 0.5M KC1, 50 mM MgCl,, and 50 
our goals included the development of DNAs that could mM HEPES (PH 7.0) at 23” C. Next, 1 mM PbOAc was 
carry out Pb2+-dependent cleavage of a particular RNA provided in the same buffer, allowing Pb2+-dependent cleav- 
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age to occur at the target phosphoester, thereby releasing a The 28-nucleotide 5’ cleavage product (Clv) illustrated 
subset of the DNAs from the streptavidin matrix. In p r e f e r a b l y  h a s  t h e  s e q u e n c e  
principle, an individual DNA might facilitate its own release 5’ - G G GACGAATTCTAATACGACTCACTATN-3, 
by various means, such as disruption of the interaction wherein “N’  represents adenosine ribonucleotide with an 
between biotin and streptavidin or cleavage of one of the s additional 2’, 3’-cyclic phosphate on the 3’ end (SEQ ID NO 
deoxyribonucleotide linkages. It was felt that cleavage of the 5). In alternative embodiments, “N’  represents adenosine 
ribonucleoside 3’-0-P bond would be the most likely mecha- ribonucleotide with an additional 2’ or 3’ phosphate on the 3’ 
nism for release, based on the relative lability of this linkage, end of the molecule. 
and that Pb2+-dependent hydrolytic cleavage would allow In FIG. 2, the “GO” lane “Pre” band comprises a sampling 
release to occur most rapidly. In principle, however, the in i o  of 108-nucleotide precursor DNAs that each include 50 
vitro selection procedure should identify the most favorable random nucleotides. Therefore, any given “Pre” sampling 
release mechanism as well as those individuals best able to will contain a wide variety of precursor DNAs, and each 
carry out that mechanism. sampling will likely differ from previous and subsequent 
DNAmolecules released from the matrix upon addition of samplings. The “Gl” through “G5” lanes contain “Pre” 
Pb2+were collected in the eluant, concentrated by precipi- is bands that are increasingly enriched for catalytic DNA 
tation with ethanol, and subjected to nested PCR amplifi- molecules, but still contain a large number of different DNA 
cation. As in the construction of the starting pool of sequences (i.e., differing in the 50 nucleotide randomized 
molecules, the first PCR amplification utilized primers that domain). A sample of these different sequences from “G5 
flank the random region (primers 1 and 2) and the second Pre” DNA is provided in FIG. 3. 
utilized a 5’-biotinylated primer (primer 3b) that has a 20 Shotgun cloning techniques were employed to isolate 
3’-terminal riboadenylate, thereby reintroducing the target individuals from the G5 population; the complete nucleotide 
RNA phosphoester. The entire selective amplification pro- sequences of 20 of these subclones were then determined 
cedure requires 3-4 hours to perform. (see FIG. 3). (Also see, e.g., Cadwell and Joyce, in PCR 
The molecules are purified in three ways during each Methods and Applications 2: 28-33 (1992); Cadwell and 
round of this procedure: first, following PCR amplification, zs Joyce, PCR Methods and Applications 3 (Suppl.): 
by extracting twice with phenol and once with chloroform/ S136-S140 (1994).) Of the 20 sequences, five were unique, 
isoamyl alcohol, then precipitating with ethanol; second, two occurred twice, one occurred three times, and one 
following attachment of the DNA to streptavidin, by wash- occurred eight times. All of the individual variants share 
ing away all the nonbiotinylated molecules under strongly common sequence elements within the 50-nucleotide region 
denaturing conditions; and third, following elution with 30 that had been randomized in the starting pool of DNA. They 
Pb2+, by precipitating with ethanol. There is no gel electro- all contain two presumed template regions, one with 
phoresis purification step, and thus no selection pressure complementarity to a stretch of nucleotides that lies just 
constraining the molecules to a particular length. upstream from the cleavage site and the other with comple- 
C. Selection of Catalytic DNA mentarity to nucleotides that lie at least four nucleotides 
We carried out five successive rounds of in vitro selection, 3s downstream. Between these two presumed template regions 
progressively decreasing the reaction time following addi- lies a variable domain of 1-11 nucleotides, followed by the 
tion of Pb2+in order to progressively increase the stringency fixed sequence 5’-AGCG-3’, then a second variable domain 
of selection. During rounds 1 through 3, the reaction time of 3-8 nucleotides, and finally the fixed sequence 5’-CG-3’ 
was 1 hour; during round 4, it was 20 minutes; and during or 5’-CGA-3’. Nucleotides that lie outside of the two pre- 
round 5, it was 1 minute. The starting pool of single-stranded 40 sumed template regions are highly variable in both sequence 
DNAs, together with the population of molecules obtained and length. In all of the sequenced subclones, the region 
after each round of selection, was assayed for self-cleavage corresponding to the 50 initially-randomized nucleotides 
activity under conditions identical to those employed during remains a total of 50 nucleotides in length. 
in vitro selection (see FIG. 2). FIG. 3 illustrates the sequence alignment of individual 
For this assay, the molecules were prepared with a 5’-32p 4s variants isolated from the population after five rounds of 
rather than a 5’-biotin moiety, allowing detection of both the s e l e c t i o n  . T h e  f ixed  s u b s t r a t e  d o m a i n  (5 ’ - 
starting material and the 5’ cleavage product. Following a GGGACGAATTCTAATACGACTCACTATrAGGAAGAG 
5-minute incubation, there was no detectable activity in the ATGGCGAC-3’, or 5’-GGGACGAATTCTAATACGACT 
initial pool (GO) or in the population obtained after the first CACTATNGGAAGAGATGGCGAC-3’, where N repre- 
and second rounds of selection. DNAs obtained after the SO sents adenosine ribonucleotide) (SEQ ID NO 13) is shown 
third round (G3) exhibited a modest level of activity and this at the top, with the target riboadenylate identified with an 
activity increased steadily, reaching approximately 50% inverted triangle. Substrate nucleotides that are commonly 
self-cleavage for the DNAs obtained after the fifth round of involved in presumed base-pairing interactions are indicated 
selection (G5). Cleavage was detected only at the target by a vertical bar. Sequences corresponding to the 50 
phosphoester, even after long incubation times. This activity ss initially-randomized nucleotides are aligned antiparallel to 
was lost if Pb2+ was omitted from the reaction mixture. the substrate domain. All of the variants are 3’-terminated by 
FIG. 2 illustrates the self-cleavage activity of the starting the fixed sequence 5’-CGGTAAGCTTGGCAC-3’(SEQ ID 
pool of DNA (GO ) and populations obtained after the first NO 1) (“primer site”; not shown). Nucleotides within the 
through fifth rounds of selection (Gl-G5). Reaction mix- initially-randomized region that are presumed to form base 
tures contained 50 mM MgCl,, 0.5M NaC1, 0.5M KC1, 50 60 pairs with the substrate domain are indicated on the right and 
mM HEPES (pH 7.0 at 23” C.), and 3 nM [5’-32P]-labeled left sides of the Figure; the putative base-pair-forming (or 
DNA, incubated at 23” C. for 5 min in either the presence or substrate binding) regions of the enzymatic DNAmolecules 
absence of 1 mM PbOAc. The symbol Pre represents are individually boxed in each sequence shown. The highly- 
108-nucleotide precursor DNA (SEQ ID NO 4); Clv, conserved nucleotides within the putative catalytic domain 
28-nucleotide 5’-cleavage product (SEQ ID NO 5); and M, 65 are illustrated in the two boxed columns. 
primer 3a (SEQ ID NO 6), corresponding in length to the While it is anticipated that additional data will be helpful 
5’-cleavage product. in constructing a meaningful secondary structural model of 
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the catalytic domain, we note that, like the hammerhead and equimolar mixture of G, A, T and C. A2-ml PCR, containing 
hairpin ribozymes, the catalytic domain of our enzymatic 500 pmoles of the randomized oligomer, 1,000 pmoles 
DNAmolecules appears to contain a conserved core flanked primer 1 (5'-GTGCCAAGCTTACCG-3', SEQ ID NO lo), 
by two substrate binding regions (or recognition domains) 500 pmoles primer 2 (5'-CTGCAGAATTCTAAT 
that interact with the substrate through base-pairing inter- s ACGACTCACTNAGGAAGAGATGGCGAC-3', SEQ ID 
actions. Similar to the hammerhead and hairpin ribozymes, NO l l ) ,  500 pmoles primer 3b, 1OpCi [a-32P]dATP, and 0.2 
the catalytic DNAs also appear to require a short stretch of U pl-1 Taq DNApolymerase, was incubated in the presence 
unpaired substrate nucleotides-in this case 5'-GGA-3'- of 50 mM KC1, 1.5 mM MgCl,, 10 mM Tris-HC1 (PH 8.3 at 
between the two regions that are involved in base pairing. 23" C.), 0.01% gelatin, and 0.2 mM of each dNTP for 1 rnin 
It was also interesting to note that each of the nine distinct i o  at 92" C., 1 rnin at 50" C., and 2 rnin at 72" C., then 5 cycles 
variants exhibited a different pattern of presumed comple- of 1 rnin at 92" C., 1 rnin at 50" C., and 1 rnin at 72" C. The 
mentarity with the substrate domain. In some cases, base resulting mixture was extracted twice with phenol and once 
pairing was contiguous, while in others it was interrupted by with chloroformiisoamyl alcohol, and the DNAwas isolated 
one or more noncomplementary pairs. The general tendency by precipitation with ethanol. 
seems to be to form tighter interaction with the nucleotides is C. In Vitro Selection 
that lie upstream from the cleavage site compared to those The starting pool of DNA was resuspended in 500 pL of 
that lie downstream. Binding studies and site-directed buffer A (1M NaCl and 50 mM HEPES (PH 7.0 at 23" C.)) 
mutagenesis analysis should enable us to gain further and was passed repeatedly over a streptavidin column 
insights and to further substantiate this conjecture. (AfhiTip Strep 20, Genosys, The Woodlands, Tex.). The 
In order to gain further insight into the sequence require- 20 column was washed with five 100-pl volumes of buffer A, 
ments for catalytic function, the self-cleavage activity of six followed by five 100-pl volumes of 0.2N NaOH, then 
of the nine variants was tested and evaluated under the equilibrated with five 100-pl volumes of buffer B (0.5M 
within-described selection conditions (see FIG. 3). Not NaC1, 0.5M KC1, 50 mM MgCl,, and 50 mM HEPES (PH 
surprisingly, the sequence that occurred in eight of the 20 7.0 at 23" C.)). The immobilized single-stranded DNA was 
subclones proved to be the most reactive, with a first-order zs eluted over the course of 1 hr with three 20-pl volumes of 
rate constant of 1.4 rnin-'. All of the studied variants were buffer B with added 1 mM PbOAc. The entire immobiliza- 
active in the self-cleavage assay and all gave rise to a single tion and elution process was conducted at 23" C. The eluant 
5'-labeled product corresponding to cleavage at the target was collected in an equal volume of buffer C (50 mM 
RNA phosphoester. HEPES (PH 7.0 at 23" C.) and 80 mM EDTA) and the DNA 
variety of reaction conditions. Its self-cleavage activity was The resulting DNA was amplified in a 100-pL PCR 
dependent on Pb2+ but was unaffected if Mg2+ was omitted containing 20 pmoles primer 1, 20 pmoles primer 2,0.05 U 
from the reaction mixture. There was a requirement for a p1-1 Taq polymerase, 50 mM KC1, 1.5 mM MgCl,, 10 mM 
monovalent cation as well, which can be met by either Na+ Tris-HC1 (PH 8.3 at 23" C.), 0.01% gelatin, and 0.2 mM of 
or K+. The reaction rate increased linearly with increasing 3s each dNTP for 30 cycles of 10 sec at 92" C., 30 sec at 50" 
concentration of monovalent cation over the range of C., and 30 sec at 72" C. The reaction products were extracted 
0-1.OM (r=0.998). Other variables that might affect the twice with phenol and once with chloroformiisoamyl 
reaction, such as pH, temperature, and the presence of other alcohol, and the DNA was recovered by precipitation with 
divalent metals, are in the process of being evaluated. ethanol. Approximately 4 pmoles of the amplified DNA was 
40 added to a second, nested PCR containing 100 pmoles Example 2 primer 1, 100 pmoles primer 3b, 20 pCi [a-3zP]dATP, and 
Materials and Methods 0.1 U pl-1 Taq polymerase, in a total volume of 200 pL that 
A. Oligonucleotides and Oligonucleotide Analogues was amplified for 10 cycles of 1 rnin at 92" C., 1 rnin at 50" 
Synthetic DNAs and DNA analogues were purchased C., and 1 rnin at 72" C. The PCR products were once more 
from Operon Technologies. The 19-nucleotide substrate, 4s extracted and precipitated, and the resulting DNA was 
5 ' - p T C A C TATr  A G G A A  G A G A T  G G - 3 ' ( o r resuspended in 50 pL buffer A, then used to begin the next 
5'-pTCACTATNGGAAGAGATGG-3', wherein "N' repre- round of selection. 
sents adenosine ribonucleotide) (SEQ ID NO 7), was pre- The second and third rounds were carried out as above, 
pared by reverse-transcriptase catalyzed extension of except that the nested PCR at the end of the third round was 
5'-pTCACTATrA-3' (or 5'-pTCACTATN-3', wherein "N' SO performed in a 100-pl volume. During the fourth round, the 
represents adenosine ribonucleotide) (SEQ ID NO 8), as elution time following addition of Pb2+was reduced to 20 
previously described (Breaker, Banerji, & Joyce, Biochem- rnin (two 20-pL elution volumes) and only half of the 
istry 33: 11980-11986 (1994)), using the template recovered DNA was used in the first PCR, which involved 
5'-CCATCTCTTCCTATAGTGAGTCCGGCTGCA-3', only 15 temperature cycles. During the fifth round, the 
( S E Q  I D  NO 9 ) .  P r i m e r  3 ,  ss elution time was reduced to 1 rnin (two 20-pL elution 
5'-GGGACGAATTCTAATACGACTCACTATrA-3' (or volumes) and only one-fourth of the recovered DNA was 
5'-GGGACGAATTCTAATACGACTCACTATN-3', used in the first PCR, which involved 15 temperature cycles. 
wherein "N' represents adenosine ribonucleotide) (SEQ ID DNA obtained after the fifth round of selection was sub- 
NO 6), was either 5'-labeled with [Y-~'P]ATP and T4 poly- cloned and sequenced, as described previously (Tsang & 
nucleotide kinase (primer 3a) or 5'-thiophosphorylated with 60 Joyce, Biochemistry 33: 5966-5973 (1994)). 
[y-SIATP and T4 polynucleotide kinase and subsequently D. Kinetic Analysis of Catalytic DNAs 
biotinylated with N-iodoacetyl-N'-biotinylhexylenediamine Populations of DNA and various subcloned individuals 
(primer 3b). were prepared with a 5I3'P label by asymmetric PCR in a 
B. DNA Pool Preparation 25-p1 reaction mixture containing 10 pmoles primer 3a, 0.5 
The starting pool of DNAwas prepared by PCR using the 65 pmoles input DNA, and 0.1 U pl-1 Taq polymerase, under 
synthetic oligomer 5'-GTGCCAAGCTTACCG-N,,- conditions as described above, for 10 cycles of 1 rnin at 92" 
GTCGCCATCTCTTCC-3' (SEQ ID NO 4), where N is an C., 1 rnin at 50" C., and 1 rnin at 72" C. The resulting 
The dominant subclone was further analyzed under a 30 was precipitated with ethanol. 
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[5’-32P]-labeled amplification products were purified by sequence, allows efficient DNA-catalyzed phosphoester 
electrophoresis in a 10% polyacrylamidei8M gel. cleavage with rapid turnover. Over a 90-minute incubation 
Self-cleavage assays were carried out following preincu- in the presence of 0.01 catalyst and 1 substrate, 46% 
initiated by addition of pboAc to 1 m~ final concentration 5 the catalyst. A preliminary kinetic analysis of this reaction 
and were terminated by addition of an equal volume of was carried out, evaluated under multiple-turnover condi- 
buffer C, ~~~~~i~~ products were separated by electrophore- tions. The DNAcatalyst exhibits Michaelis-Menten kinetics, 
bation of the DNA in buffer B for 10 min, Reactions were Of the substrate is cleaved, corresponding to 46 turnovers Of 
sis in a 10% polyacrylamide/8M gel, Kinetic assays under with for kc,, and Of min-l and pM, respec- 
multiple-turnover conditions were carried out in buffer B tively (see 4B). The for k is 
that included 5o pg ml- -~  BSA to prevent adherence of greater than the expected dissociation constant between catalyst and substrate based on Watson-Crick interactions. to the Substrate and enzyme The substrate was incubated under identical reaction condi- ecules were preincubated for min in reaction tions (but in the absence of the catalyst); a value for k,,,,, 
buffer that lacked Pb2+, then combined, and the reaction was 
initiated by addition of PbOAc to a final concentration of 1 
mM. 
Example 3 
Evolution of Deoxyribozymes That Cleave 
Intermolecularly 
of 4x10-6 min-i was obtained, mis is consistent with the 
reported value of 5x10-3 min-i for hydrolysis of the 
labile l-nitrophenyl-1,2-propanediol in the presence of 0.5 
mM Pb2+ at pH 7.0 and 37” C. (Breslow & Huang, PNAS 
USA 88: 408Ck4083 (1991)). 
It is now presumed that the phosphoester cleavage reac- 
tion proceeds via a hydrolytic mechanism involving attack 
A. Conversion to an Intermolecular Format 20 by the ribonucleoside 2’-hydroxyl on the vicinal phosphate, 
Based on the variable pattern of presumed base-pairing generating a 5’ product with a terminal 2’(3’)-cyclic phos- 
interactions between the catalytic and substrate domains of phate and 3’ product with a terminal 5’-hydroxyl. In support 
the studied variants, it was felt that it would be reasonably of this mechanism, the 3’-cleavage product is efficiently 
straightforward to convert the DNA-catalyzed reaction to an phosphorylated with T4 polynucleotide kinase and [Y-~’P] 
intermolecular format. In doing so, we wished to simplify zs ATP, consistent with the availability of a free 5’-hydroxyl 
the two substrate-binding regions of the catalyst so that each (data not shown). 
would form an uninterrupted stretch of 7-8 base pairs with B. Discussion 
the substrate. In addition, we wished to provide a minimal After five rounds of in vitro selection, a population of 
substrate, limited to the two base-pairing regions and the single-stranded DNA molecules that catalyze efficient Pb2+ 
intervening sequence 5’-GGA-3’ (FIG. 4A). 30 -dependent cleavage of a target RNA phosphoester was 
FIGS. 4Aand 4B illustrate DNA-catalyzed cleavage of an obtained. Based on the common features of representative 
RNA phosphoester in an intermolecular reaction that pro- individuals isolated from this population, a simplified ver- 
ceeds with catalytic turnover. FIG. 4A is a diagrammatic sion of both the catalytic and substrate domains was 
representation of the complex formed between the 19mer constructed, leading to a demonstration of rapid catalytic 
substrate and 38mer DNA enzyme. The substrate contains a 35 turnover in an intermolecular context. Thus the 38mer 
single adenosine ribonucleotide (“rA” or “N’, adjacent to catalytic domain provides an example of a DNA enzyme, or 
the arrow), flanked by deoxyribonucleotides. The synthetic what might be termed a “deoxyribozyme”. 
DNA enzyme is a 38-nucleotide portion of the most fre- Referring to this molecule as an enzyme, based on the fact 
quently occurring variant shown in FIG. 3. Highly- that it is an informational macromolecule capable of accel- 
conserved nucleotides located within the putative catalytic 40 erating a chemical transformation in a reaction that proceeds 
domain are “boxed”. As illustrated, one conserved sequence with rapid turnover and obeys Michaelis-Menten kinetics, 
is “AGCG’, while another is “CG’ (reading in the 5’+3’ may not satisfy everyone’s notion of what constitutes an 
direction). enzyme. Some might insist that an enzyme, by definition, 
FIG. 4B shows an Eadie-Hofstee plot used to determine must be a polypeptide. If, however, one accepts the notion 
K, (negative slope) and V, (y-intercept) for DNA- 45 of an RNA enzyme, then it seems reasonable to adopt a 
catalyzed cleavage of [5’-32P]-labeled substrate under con- similar view concerning DNA enzymes. Considering how 
ditions identical to those employed during in vitro selection. quickly we were able to generate this molecule from a pool 
Initial rates of cleavage were determined for reactions of random-sequence DNAs, we expect that many other 
involving 5 nM DNA enzyme and either 0.125,0.5, 1, 2, or examples of synthetic DNA enzymes will appear in the near 
4 pM substrate. SO future. 
In designing the catalytic domain, we relied heavily on the The Pb2+-dependent cleavage of an RNA phosphoester 
composition of the most reactive variant, truncating by two was chosen as an initial target for DNA catalysis because it 
nucleotides at the 5’ end and 11 nucleotides at the 3’ end. The is a straightforward reaction that simply requires the proper 
15 nucleotides that lay between the two template regions positioning of a coordinated Pb2+-hydroxyl to facilitate 
were left unchanged and a single nucleotide was inserted ss deprotonation of the 2’ hydroxyl that lies adjacent to the 
into the 3’ template region to form a continuous stretch of cleavage site. (See, e.g., Pan, et al., in The RNA World, 
nucleotides capable of forming base pairs with the substrate. Gesteland & Atkins (eds.), pp. 271-302, Cold Spring Harbor 
The substrate was simplified to the sequence 5’- Laboratory Press, Cold Spring Harbor, N.Y. (1993).) Pb2+ is 
TCACTATrA.GGAAGAGATGG-3’(or 5’- known to coordinate to the N7 position of purines, the 0 6  
TCACTATN.GGAAGAGATGG-3’, wherein “N’  represents 60 position of guanine, the 0 4  position of uracil, and the N3 
adenosine ribonucleotide) (SEQ ID NO 12), where the position of cytosine (Brown, et al., Nature 303: 543-546 
underlined nucleotides correspond to the two regions (1993)). Thus, the differences in sugar composition and 
involved in base pairing with the catalytic DNA molecule. conformation of DNAcompared to RNAseemed unlikely to 
The simplified reaction system, employing a 38mer cata- prevent DNA from forming a well-defined Pb2+-binding 
lytic DNA molecule (catalyst) comprised entirely of deox- 65 pocket. 
yribonucleotides and a 19mer substrate containing a single A substrate that contains a single ribonucleotide within an 
ribonucleotide embedded within an otherwise all-DNA otherwise all-DNAsequence was chosen because it provided 
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a uniquely favored site for cleavage and insured that any 
resulting catalytic activity would be attributable solely to 
DNA. Substrate recognition appears to depend on two 
regions of base-pairing interactions between the catalyst and 
substrate. However, the unpaired substrate nucleotides, 
5'-GGA-3', that lie between these two regions may play an 
important role in substrate recognition, metal coordination, 
or other aspects of catalytic function. 
It is further anticipated that an all-RNA molecule, other 
RNA-DNA composites, and molecules containing one or 
more nucleotide analogs may be acceptable substrates. As 
disclosed herein, the within-described in vitro evolution 
procedures may successfully be used to generate enzymatic 
DNA molecules having the desired specificities; further 
analyses along these lines are presently underway. 
In addition, studies to determine whether the presumed 
base-pairing interactions between enzyme and substrate are 
generalizable with respect to sequence are in progress, using 
the presently-described methods. The within-disclosed Pb2+ 
-dependent deoxyribozymes may also be considered model 
compounds for exploring the structural and enzymatic prop- 
erties of DNA. 
The methods employed in the present disclosure for the 
rapid development of DNA catalysts will have considerable 
generality, allowing us to utilize other cofactors to trigger 
the cleavage of a target linkage attached to a potential 
catalytic domain. In this regard, the development of Mg2+- 
dependent DNA enzymes that specifically cleave target 
RNAs under physiological conditions is of interest. Such a 
molecule will provide an alternative to traditional antisense 
and ribozyme approaches for the specific inactivation of 
target mRNAs. 
DNA thus joins RNA and protein on the list of biological 
macromolecules that are capable of exhibiting enzymatic 
activity. The full extent of DNA's catalytic abilities remains 
to be explored, but these explorations should proceed rap- 
idly based on in vitro selection methods such as those 
employed in this study. 
DNA enzymes offer several important advantages com- 
pared to other macromolecular catalysts. First, they are easy 
to prepare, in an era when most laboratories have access to 
an automated DNA synthesizer and the cost of DNA phos- 
phoramidites has become quite modest. Second, they are 
very stable compounds, especially compared to RNA, thus 
facilitating their use in biophysical studies. Third, we expect 
that they can be adapted to therapeutic applications that at 
present make use of antisense DNAs that lack RNA- 
cleavage activity. In vitro selection could be carried out with 
DNA analogues, including compounds that are nuclease 
resistant such as phosphorothioate-containing DNA, so long 
as these analogues can be prepared in the form of a deoxy- 
nucleoside 5'-triphosphate and are accepted as a substrate by 
a DNA-dependent DNApolymerase. Finally, DNAenzymes 
offer a new window on our understanding of the macromo- 
lecular basis of catalytic function. It will be interesting, for 
example, to carry out comparative analyses of protein-, 
RNA-, and DNA-based enzymes that catalyze the same 
chemical transformation. 
Example 4 
Other Families of Catalytic DNAs 
A starting pool of DNA was prepared by PCR essentially 
as described in Example 2.B. above, except that the starting 
pool of DNA comprised molecules containing 40 random 
nucleotides. Thus, the starting pool of DNAdescribed herein 
was prepared by PCR using the synthetic oligomer 5' GGG 
5 
10 
1s 
20 
2s 
30 
3s 
40 
4s 
so 
5s 
60 
65 
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ACG AAT TCT AAT ACG ACT CAC TAT rA GG AAG 
AGA TGG CGA CAT CTC N,,GT GAC GGT AAG CTT 
GGC AC 3' (SEQ ID NO 23), where N is an equimolar 
mixture of G, A, T and C, and where the DNA molecules 
were selected for the ability to cleave the phosphoester 
following the target rA. (See FIG. 6A, also.) Selective 
amplification was carried out in the presence of either Pb2+, 
Zn", Mn", or Mg2+, thereby generating at least four 
"families" of catalytic DNA molecules. As illustrated in 
FIG. 5, catalytic DNA molecules demonstrating specific 
activity were generated in the presence of a variety of 
cations. 
FIG. 5 is a photographic representation showing a poly- 
acrylamide gel demonstrating specific endoribonuclease 
activity of four families of selected catalytic DNAs. Selec- 
tion of a Pb2+-dependent family of molecules was repeated 
in a side-by-side fashion as a control. In each group of three 
lanes, the first lane shows the lack of activity of the selected 
population in the absence of the metal cation, the second 
lane shows the observed activity in the presence of the metal 
cation, and the third lane shows the lack of activity of the 
starting pool (GO). At present, the order of reactivity is 
observed to be Pb2+>Zn2+>Mn2+>Mg2+, mirroring the pK, 
of the corresponding metal-hydroxide. 
After either five (G5) or six (G6) rounds of selective 
amplification in the presence of the preselected divalent 
cation, the desired endonuclease activity was obtained. The 
following description of selective amplification in the pres- 
ence of Mg2+is intended to be exemplary. 
Six rounds of in vitro selective amplification were carried 
out, following the method described in Example 2 
hereinabove, except that the divalent metal used was 1 mM 
Mg2+ rather than 1 mM Pb2+. (See also Breaker and Joyce, 
Chern. & Biol. 1: 223-229 (1994), incorporated by reference 
herein, which describes essentially the same procedure.) 
Individual clones were isolated following the sixth round, 
and the nucleotide sequence of 24 of these clones was 
determined. All of the sequences began with: 5' GGG ACG 
AAT TCT AAT ACG ACT CAC TAT rA GG AAG AGA 
TGG CGA CA (SEQ ID NO 23 from position 1 to 44) and 
ended with: CGG TAA GCT TGG CAC 3' (SEQ ID NO 23 
from position 93 to 107). 
The segment in the middle, corresponding to TCTC N,, 
GTGA (SEQ ID NO 23 from position 45 to 92) in the 
starting pool, varied as follows: 
(13) CCG CCC ACC TCT TlT ACG AGC CTG TAC GAA ATA 
GTG CTC T I G  T I A  GTA T (SEQ ID NO 24) 
(5) TCT C T I  CAG CGA TGC ACG C T I  G T I  T I A  ATG T I G  
CAC CCA TGT TAG TGA (SEQ ID NO 25) 
(2) TCT CAT CAG CGA T I G  AAC CAC T I G  GTG GAC AGA 
CCC ATG T I A  GTG A (SEQ ID NO 26) 
(1) CCG CCC ACC TCT TlT ACG AGC CTG TAC GAA ATA 
GTG T I C  T I G  T I A  GTA T (SEQ ID NO 27) 
(1) CCG CCC ACC TCT TlT ACG AGC CTG TAC GAA ATA 
GTG CTC TCG T I A  GTA T (SEQ ID NO 28) 
(1) TCT CAG ACT TAG TCC ATC ACA CTC TGT GCA TAT 
GCC TGC T I G  ATG TGA (SEQ ID NO 29) 
(1) -CT CTC ATC TGC TAG CAC GCT CGA ATA GTG TCA 
GTC GAT GTG A (SEQ ID NO 30). 
The initial number in parentheses indicates the number of 
clones having that particular sequence. Note that some 
mutations (highlighted in bold type) occurred at nucleotide 
positions other than those that were randomized initially. 
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The second sequence listed above (i.e., SEQ ID NO 25), 
which occurred in 5 of 24 clones, was chosen as a lead 
compound for further study. Its cleavage activity was mea- 
sured in the presence of a 1 mM concentration of various 
-continued 
(1)ATC AGC GAT TCA CCC - TAA GGT TGC ACC 
GTI A (SEQ ID No 34) 
divalent metals and 1M NaCl at pH 7.0 and 23” C.: (1) ATC AGC GAT TCA CCC T I G  TlT AAG CGT TAC ACC 
CAT G T I  G (SEQIDNO35) 
(1)ATC AGC GAT TCA CCC T I G  TlT TAA GGT TAC ACC 
CAT G T I  A (SEQIDNO36) 
none 
MgZf 
Mn2+ 
Zn2+ 
Pb2+ 
n.d. 
2.3 10-3 
6.8 x 
4.2 x lo-’ 
1.1 x 10-2 
10 (1)ATC AGC GAT TAA CGC T I A  TlT TAG CGT TAC ACC 
CAT G T I  A (SEQIDNO37) 
(1)ATC AGC GAT TAA CGC T I G  TlT TAG TGT TGC ACC 
CAT G T I  A (SEQIDNO38) 
15 (1)ATC AGC GAT TAA CGC T I A  TlT TAG CAT TAC ACC 
Thus, the lead compound is active in the presence of all CAT G T I  A (SEQIDNO39). 
four divalent metals, even though it was selected for activity 
in the presence of Mg2+. Conversely, DNA molecules that 
The number in parentheses indicates the number of clones were selected for activity in the presence of Mn”, Zn”, or 
Pb2+ did not show any activity in the presence of M ~ z + ,  2o having that particular sequence. Nucleotides shown in bold 
In addition, the population of DNAs obtained after six 
rounds of in vitro selection in the presence of Mg2+, when Formal analysis of the cleavage activity of these clones is 
prepared as all-phosphorothioate- containing DNA ongoing. The population as a whole exhibits Mg2+- 
analogues, showed Mg2+-dependent cleavage activity at an dependent cleavage activity at an observed rate of -lo-’ 
containing analogues were prepared enzymatically so as to of pb2+. 
have an R, configuration at each stereocenter. Such com- 
pounds are relatively resistant to degradation by cellular FIGS. 6A and 6B provide two-dimensional illustrations of 
nucleases compared to unmodified DNA. a “progenitor” catalytic DNA molecule and one of several 
30 catalytic DNA molecules obtained via the selective ampli- 
fication methods disclosed herein, respectively. FIG. 6A positions (underlined), introducing mutations at a frequency illustrates an exemplary molecule from the starting pool, 
sented by SEQ ID NO 23. As illustrated, various comple- substitutions). The re-randomized population was subjected to seven additional rounds of in vitro selection. During the 
last four rounds, molecules that were reactive in the presence 
of 1 mM Pb2+were removed from the population before the FIG. 6B is a diagrammatic representation of one of the 
remainder were challenged to react in the presence of 1 mM Mg2+-dependent  ca t a ly t i c  D N A  molecu le s  (o r  
Mg2+. Individual clones were isolated following the seventh “DNAzymes”) generated via the within-described proce- 
round and the nucleotide sequence of 14 of these clones was 4o dures (SEQ ID NO 40). The location of the ribonucleotide 
determined. All of the , sequences began with: 5’ GGG ACG in the substrate nucleic acid is indicated via the arrow. (The 
AAT TCT AAT ACG ACT CAC TAT rA GG AAG AGA illustrated molecule includes the sequence identified herein 
TGG CGA CAT CTC (SEQ ID NO 23, from position 1 to as SEQ ID NO 25, as well as “beginning” and “ending” 
48), and ended with: GTG ACG GTAAGC TTG GCA C 3’ sequences of SEQ ID NO 23.) 
Endonuclease activity is continuing to be enhanced in (SEQ ID NO 23, from position 89 to 107). 
The segment in the middle, corresponding to the 40 each of the aforementioned “families” via in vitro evolution, 
partially-randomized positions (N40, SEQ ID NO 23, from as disclosed herein, so it is anticipated that enzymatic DNA 
position 49 to 88), varied as follows: molecules of increasingly desirable specificities may be 
generated successfully using the within-disclosed guide- 
The foregoing specification, including the specific 
(2) ATC AGC GAT TAA CGC T I G  TlT CAA TGT TAC ACC embodiments and examples, is intended to be illustrative of 
the present invention and is not to be taken as limiting. 
(2) AGC GAT CGC TIA TAG cGT TAc ACC 55 Numerous other variations and modifications can be effected 
without departing from the true spirit and scope of the 
present invention. 
are those that differ compared to the lead compound. 
observed rate of min-l . The phosphorothioate- 25 min-’ , with a comparable level of activity in the presence 
The lead was re-randomized at 40 
Of 15% (5% probability Of each Of the three possible base showing the overall configuration of the molecules repre- 
35 mentary nucleotides flank the random (N40) region. 
45 
(4)TAC AGC GAT TCA CCC T I G  TlT AAG GGT TAC ACC 50 lines. 
CAT G T I  A (SEQIDNO31) 
CAT G T I  A (SEQIDNO32) 
CAT G T I  A (SEQIDNO33) 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION 
( i i i ) NUMBER OF SEQUENCES: 40 
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-continued 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 15 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:1: 
C G G T A A G C T T  G G C A C  
( 2 ) INFORMATION FOR SEQ ID N O 2  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 20 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(8, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID N O 2  
T C A C T A T N A G  G A A G A G A T G G  
( 2 ) INFORMATION FOR SEQ ID NO:3: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 38 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:3: 
A C A C A T C T C T  G A A G T A G C G C  C G C C G T A T A G  T G A C G C T A  
( 2 ) INFORMATION FOR SEQ ID NO:4 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 80 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:4: 
G T G C C A A G C T  T A C C G N N N N N  N N N N N N N N N N  N N N N N N N N N N  N N N N N N N N N N  N N N N N N N N N N  
N N N N N G T C G C  C A T C T C T T C C  
( 2 ) INFORMATION FOR SEQ ID N O 5  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 28 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY miscfeature 
2 0  
3 8  
6 0  
8 0  
5,807,718 
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( B ) LOCATION 28 
( D ) OTHER INFORMATION /standarddame= "2'3'CYCLIC 
PHOSPHATE" 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(28, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:S: 
G G G A C G A A T T  C T A A T A C G A C  T C A C T A T N  
( 2 ) INFORMATION FOR SEQ ID NO:6: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 28 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(28, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:6: 
G G G A C G A A T T  C T A A T A C G A C  T C A C T A T N  
( 2 ) INFORMATION FOR SEQ ID NO:T 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 19 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(8, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:7: 
T C A C T A T N G G  A A G A G A T G G  
( 2 ) INFORMATION FOR SEQ ID NO:8 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 8 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(8, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
NUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID NOS: 
T C A C T A T N  
2 8  
2 8  
1 9  
( 2 ) INFORMATION FOR SEQ ID NO:9: 
8 
5,807,718 
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( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 30 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:9: 
C C A T C T C T T C  C T A T A G T G A G  T C C G G C T G C A  
( 2 ) INFORMATION FOR SEQ ID NO:10: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 15 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:lO 
G T G C C A A G C T  T A C C G  
( 2 ) INFORMATION FOR SEQ ID N0:l l :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 43 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:l l :  
C T G C A G A A T T  C T A A T A C G A C  T C A C T A T A G G  A A G A G A T G G C  G A C  
( 2 ) INFORMATION FOR SEQ ID NO:12: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 19 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY misc_difference 
( B ) LOCATION replace(8, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:12: 
T C A C T A T N G G  A A G A G A T G G  
( 2 ) INFORMATION FOR SEQ ID NO:13: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 43 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY misc_difference 
( B ) LOCATION replace(28, "") 
( D ) OTHER INFORMATION /standard_name= "ADENOSINE 
RIBONUCLEOTIDE" 
3 0  
4 3  
1 9  
5,807,718 
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( x i ) SEQUENCE DESCRIPTION SEQ ID NO:13: 
G G G A C G A A T T  C T A A T A C G A C  T C A C T A T N G G  A A G A G A T G G C  G A C  
( 2 ) INFORMATION FOR SEQ ID NO:14: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:14 
T C A C A C A T C T  C T G A A G T A G C  G C C G C C G T A T  G T G A C G C T A G  G G G T T C G C C T  
( 2 ) INFORMATION FOR SEQ ID N0:lS: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:lS: 
G G G G G G A A C G  C C G T A A C A A G  C T C T G A A C T A  G C G G T T G C G A  T A T A G T C G T A  
( 2 ) INFORMATION FOR SEQ ID NO:16: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:16: 
C G G G A C T C C G  T A G C C C A T T G  C T T T T T G C A G  C G T C A A C G A A  T A G C G T A T T A  
( 2 ) INFORMATION FOR SEQ ID NO:17: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:17: 
C C A C C A T G T C  T T C T C G A G C C  G A A C C G A T A G  T T A C G T C A T A  C C T C C C G T A T  
( 2 ) INFORMATION FOR SEQ ID NO:l8: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:l8 
G C C A G A T T G C  T G C T A C C A G C  G G T A C G A A A T  A G T G A A G T G T  T C G T G A C T A T  
43 
s o  
s o  
s o  
s o  
s o  
5,807,718 
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( 2 ) INFORMATION FOR SEQ ID NO:19: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:19: 
A T A G G C C A T G  C T T T G G C T A G  C G G C A C C G T A  T A G T G T A C C T  G C C C T T A T C G  
( 2 ) INFORMATION FOR SEQ ID NO:20: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N O 2 0  
T C T G C T C T C C  T C T A T T C T A G  C A G T G C A G C G  A A A T A T G T C G  A A T A G T C G G T  
( 2 ) INFORMATION FOR SEQ ID NO:21: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO%: 
T T G C C C A G C A  T A G T C G G C A G  A C G T G G T G T T  A G C G A C A C G A  T A G G C C C G G T  
( 2 ) INFORMATION FOR SEQ ID NO%: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH SO base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N O 2 2  
T T G C T A G C T C  G G C T G A A C T T  C T G T A G C G C A  A C C G A A A T A G  T G A G G C T T G A  
( 2 ) INFORMATION FOR SEQ ID NO:23: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 107 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY misc_difference 
( B ) LOCATION replace(28, "") 
( D ) OTHER INFORMATION /standard_name= "ADENOSINE 
RIBONUCLEOTIDE" 
/ label= rA 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:23: 
G G G A C G A A T T  C T A A T A C G A C  T C A C T A T N G G  A A G A G A T G G C  G A C A T C T C N N  N N N N N N N N N N  
s o  
s o  
s o  
s o  
6 0  
5,807,718 
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N N N N N N N N N N  N N N N N N N N N N  N N N N N N N N G T  G A C G G T A A G C  T T G G C A C  
( 2 ) INFORMATION FOR SEQ ID NO:24: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 49 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO24 
C C G C C C A C C T  C T T T T A C G A G  C C T G T A C G A A  A T A G T G C T C T  T G T T A G T A T  
( 2 ) INFORMATION FOR SEQ ID NO%: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 48 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO%: 
T C T C T T C A G C  G A T G C A C G C T  T G T T T T A A T G  T T G C A C C C A T  G T T A G T G A  
( 2 ) INFORMATION FOR SEQ ID NO:26: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 46 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:26: 
T C T C A T C A G C  G A T T G A A C C A  C T T G G T G G A C  A G A C C C A T G T  T A G T G A  
( 2 ) INFORMATION FOR SEQ ID NO:27: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 49 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO27 
C C G C C C A C C T  C T T T T A C G A G  C C T G T A C G A A  A T A G T G T T C T  T G T T A G T A T  
( 2 ) INFORMATION FOR SEQ ID NO%: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 49 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO28 
C C G C C C A C C T  C T T T T A C G A G  C C T G T A C G A A  A T A G T G C T C T  C G T T A G T A T  
107 
49 
48 
46 
49 
49 
( 2 ) INFORMATION FOR SEQ ID NO:29: 
5,807,718 
48 
-continued 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 48 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:29: 
T C T C A G A C T T  A G T C C A T C A C  A C T C T G T G C A  T A T G C C T G C T  T G A T G T G A  
( 2 ) INFORMATION FOR SEQ ID NO:30: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 42 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:30 
C T C T C A T C T G  C T A G C A C G C T  C G A A T A G T G T  C A G T C G A T G T  G A  
( 2 ) INFORMATION FOR SEQ ID NO:31: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:31: 
T A C A G C G A T T  C A C C C T T G T T  T A A G G G T T A C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:32: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:32: 
A T C A G C G A T T  A A C G C T T G T T  T C A A T G T T A C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:33: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:33: 
T T C A G C G A T T  A A C G C T T A T T  T T A G C G T T A C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:34: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
4 8  
4 2  
4 0  
4 0  
4 0  
5,807,718 
49 
-continued 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:34 
A T C A G C G A T T  C A C C C T T G T T  T T A A G G T T G C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:35: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:35: 
A T C A G C G A T T  C A C C C T T G T T  T A A G C G T T A C  A C C C A T G T T G  
( 2 ) INFORMATION FOR SEQ ID NO:36: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:36: 
A T C A G C G A T T  C A C C C T T G T T  T T A A G G T T A C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:37: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:37: 
A T C A G C G A T T  A A C G C T T A T T  T T A G C G T T A C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:38: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:38: 
A T C A G C G A T T  A A C G C T T G T T  T T A G T G T T G C  A C C C A T G T T A  
( 2 ) INFORMATION FOR SEQ ID NO:39: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 40 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:39: 
4 0  
4 0  
4 0  
4 0  
4 0  
5,807,718 
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A T C A G C G A T T  A A C G C T T A T T  T T A G C A T T A C  A C C C A T G T T A  4 0  
( 2 ) INFORMATION FOR SEQ ID NO:40: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 80 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE DNA (genomic) 
( i x ) FEATURE 
( A ) NAMWKEY mist-difference 
( B ) LOCATION replace(l9, "") 
( D ) OTHER INFORMATION /standarddame= "ADENOSINE 
RIBONUCLEOTIDE" 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:40 
C T A A T A C G A C  T C A C T A T A N G  G A A G A G A T G G  C G A C A T C T C T  T C A G C G A T G C  A C G C T T G T T T  6 0  
T A A T G T T G C A  C C C A T G T T A G  8 0  
We claim: 25 SEQ ID NO 37; 
1. A catalytic DNA molecule having site-specific endo- SEQ ID NO 38; and 
nuclease activity, wherein said catalytic DNA molecule SEQ ID NO 39, 
consisting of  
comprises a sequence from the group 5 ,  The catalytic DNA molecule of claim 4, wherein said 
3o endonuclease activity is enhanced by the presence of Mg2+. 
6. The catalytic DNA molecule of claim 4, wherein said 
endonuclease activity is enhanced by the presence of a 
cation selected from the group consisting of Pb2+, Mn", 
Zn", Ca", Na+, and K+. 
7. A catalytic DNA molecule that specifically cleaves a 
substrate nucleic acid at a defined cleavage site, said cata- 
lytic DNA molecule produced by a method comprising the 
steps of  
a. admixing a population of single-stranded DNA mol- 
ecules with ribonucleotide-containing substrate nucleic 
acid molecules to form an admixture; 
b. maintaining said admixture for a sufficient period of 
time and under predetermined reaction conditions to 
allow single-stranded DNA molecules in said popula- 
tion to cause cleavage of said substrate nucleic acid 
molecules, thereby producing substrate cleavage prod- 
ucts; and 
c. isolating single-stranded PND molecules that cleave 
said substrate nucleic acid molecules from said popu- 
lation. 
8. The catalytic DNA molecule of claim 7, wherein said 
defined cleavage site comprises a single-stranded nucleic 
SEQ ID NO 3; 
SEQ ID NO 14; 
SEQ ID NO 15; 
SEQ ID NO 16; 
SEQ ID NO 17; 
SEQ ID NO 18; 
SEQ ID NO 19; 
SEQ ID NO 20; 
SEQ ID NO 21; and 
SEQ ID NO 22. 
2. The catalytic DNA molecule of claim 1, wherein said 
endonuclease activity is enhanced by the presence of Mg2+. 
3. The catalytic DNA molecule of claim 1, wherein said 
endonuclease activity is enhanced by the presence of a 45 
cation selected from the group consisting of Pb2+, Mn", 
Zn", Ca", Na+, and K+. 
4. A catalytic DNA molecule having site-specific endo- 
nuclease activity, wherein said catalytic DNA molecule 
comprises a nucleotide sequence selected from the group so 
consisting of  
35 
4o 
SEQ ID NO 23; 
SEQ ID NO 24; 
SEQ ID NO 25; 
SEQ ID NO 26; 
SEQ ID NO 27; 
SEQ ID NO 28; 
SEQ ID NO 29; 
SEQ ID NO 30; 
SEQ ID NO 31; 
SEQ ID NO 32; 
SEQ ID NO 33; 
SEQ ID NO 34; 
SEQ ID NO 35; 
SEQ ID NO 36; 
acid. 
9. The catalytic DNA molecule of claim 7, wherein said 
ss substrate comprises RNA, DNA, modified RNA, modified 
DNA, nucleotide analogs, or composites thereof. 
10. The catalytic DNA molecule of claim 7, wherein said 
catalytic DNA molecule catalyzes hydrolytic cleavage of a 
phosphoester bond at said cleavage site. 
11. The catalytic DNA molecule of claim 7, wherein said 
catalytic DNA molecule is single-stranded. 
12. The catalytic DNA molecule of claim 7, wherein said 
substrate nucleic acid is attached to said catalytic DNA 
molecule. 
13. The catalytic DNA molecule of claim 7, wherein said 
catalytic DNA molecule has a substrate binding affinity of 
about 1 pM or less. 
60 
65 
5,807,718 
53 
14. The catalytic DNA molecule of claim 7, wherein said 
catalytic DNA molecule binds substrate with a KD of less 
than about 0.1 pM. 
15. The catalytic DNA molecule of claim 7, wherein said 
catalytic DNA molecule includes a conserved nucleotide 
core comprising one or more conserved nucleotide 
sequences. 
16. A composition comprising two or more populations of 
catalytic DNAmolecules according to claim 7, wherein each 
population of catalytic DNA molecules cleaves a substrate 
nucleic acid at a different cleavage site. 
17. A composition comprising a catalytic DNA molecule 
according to claim 7 and a cation. 
18. A method of cleaving a phosphoester bond in a 
substrate, comprising: 
a. admixing the catalytic DNA molecule of claim 7 with 
phosphoester bond-containing substrate, to form a reac- 
tion admixture; 
b. maintaining said admixture under predetermined reac- 
tion conditions to allow said catalytic DNAmolecule to 
cleave said phosphoester bonds, thereby producing a 
population of cleavage products; and 
c. separating said cleavage products from said catalytic 
DNA molecule. 
19. A method of specifically cleaving a nucleic acid- 
containing substrate at a specific cleavage site, comprising 
the steps of  
a. contacting the catalytic DNA molecule of claim 7 with 
b. maintaining said admixture for a time period sufficient 
20. The catalytic DNAmolecule of claim 10, wherein said 
hydrolytic cleavage is further enhanced by the presence of a 
monovalent or divalent cation. 
21. The catalytic DNAmolecule of claim 15, wherein said 
one or more conserved nucleotide sequences are selected 
from the group consisting o f  
said substrate to form an admixture; and 
to permit cleavage of said substrate. 
CG; 
CGA, 
AGCG; 
AGCCG; 
CAGCGAT; 
CTTGTTT; and 
CTTATTT. 
22. The catalytic DNAmolecule of claim 15, wherein said 
conserved core includes at least two conserved nucleotide 
sequences, and wherein said catalytic DNAmolecule further 
comprises one or more variable or spacer nucleotides inter- 
spersed between said conserved nucleotide sequences in said 
conserved core. 
23. The catalytic DNA molecule of claim 15, further 
comprising one or more substrate binding nucleotide 
sequences. 
24. The composition according to claim 16, further com- 
prising a cation. 
25. The composition according to claim 17, wherein said 
cation is selected from the group consisting of Pb2+, MG2+, 
Mn”, Zn”, Ca”, Na+, and K+. 
26. The method of claim 18, wherein said predetermined 
reaction conditions include the addition of monovalent or 
divalent cations. 
27. The method of claim 19, further comprising the 
addition of a cation to said admixture. 
28. The catalytic DNAmolecule of claim 20, wherein said 
cation is selected from the group consisting of Pb2+, Mg2+, 
Mn”, Zn”, Ca”, Na+, and K+. 
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29. The catalytic DNAmolecule of claim 23, wherein said 
one or more substrate binding nucleotide sequences flank 
said conserved nucleotide core. 
30. The catalytic DNAmolecule of claim 23, wherein said 
s one or more substrate binding nucleotide sequences are 
selected from the group consisting of  
CATCTCT; 
GCTCT; 
TTGCTTTTT; 
TGTCTTCTC; 
TTGCTGCT; 
GCCATGCTTT (SEQ ID NO 19, residues 5-14); 
CTCTATTTCT (SEQ ID NO 20, residues 10-19): 
GTCGGCA, 
CATCTCTTC; and 
ACTTCT. 
31. The catalytic DNAmolecule of claim 23, wherein said 
20 one or more substrate binding nucleotide sequences are 
10 
1s 
selected from the group consisting of  
TATGTGACGCTA (SEQ ID NO 14, residues 28-39); 
TATAGTCGTA (SEQ ID NO 15, residues 41-50); 
ATAGCGTATTA (SEQ ID NO 16, residues 40-50); 
ATAGTTACGTCAT (SEQ ID NO 17, residues 27-39); 
AATAGTGAAGTGTT (SEQ ID NO 18, residues 28-41); 
TATAGTGTA, 
ATAGTCGGT; 
ATAGGCCCGGT (SEQ ID NO 21, residues 4Ck50); 
AATAGTGAGGCTTG (SEQ ID NO 22, residues 36-49); 
ATGNTG. 
32. The catalytic DNAmolecule of claim 23, wherein said 
one or more substrate binding nucleotide sequences are 
selected from the group consisting of  
2s 
30 
and 
3s 
TGTT; 
TGTTA, and 
TGTTAG. 
33. The catalytic DNA molecule of claim 23, further 
comprising one or more variable or spacer nucleotides that: 
a. are intercalated between said conserved core and an 
adjacent substrate binding nucleotide sequence; or 
b. are intercalated between conserved nucleotide 
sequences in said conserved core; or 
c. are intercalated between adjacent substrate binding 
nucleotide sequences; or 
d. are located at either or both termini of said catalytic 
DNA molecule; or 
e. any combination of a, b, c, and d. 
34. The composition according to claim 24, wherein said 
ss cation is selected from the group consisting of pb2+, Mg2+, 
Zn”, Ca”, Na+, and K+. 
35. The method of claim 26, wherein said cations are 
selected from the group consisting of Pb2+, Mg2+, Mn”, 
Zn”, Ca”, Na”, and K+. 
36. A method of selecting a catalytic DNA molecule that 
cleaves a substrate nucleic acid at a specific site, comprising 
the steps o f  
a. admixing a population of single-stranded DNA mol- 
ecules with ribonucleotide-containing substrate nucleic 
acid molecules, to form an admixture; 
b. maintaining said admixture for a sufficient period of 
time and under predetermined reaction conditions to 
40 
45 
so 
6o 
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allow single-stranded DNA molecules in said popula- 
tion to cause cleavage of said substrate nucleic acid 
molecules, thereby producing substrate cleavage prod- 
ucts; and 
c. isolating single-stranded DNA molecules that cleave 
said substrate nucleic acid molecules from said popu- 
lation. 
37. The method of claim 36, wherein said DNAmolecules 
c. isolating single-stranded DNA molecules that cleave 
said substrate nucleic acid molecules from said popu- 
lation. 
41. The enzymatic DNAmolecule according to claim 402 
wherein said enzymatic DNAmolecule has a binding affinity 
for said substrate and lacks a binding affinity for said 
cleavage product, 
are tagged with an immobilizing agent. 
biotin. 
39. The method of claim 38, wherein said isolating step 
further comprises exposing said tagged DNA molecules to a 
solid surface having avidin linked thereto, whereby said 
38, The method of claim 37, wherein said agent comprises 42. An enzymatic DNA molecule comprising a conserved 
10 domain flanked by two substrate binding domains, said 
enzymatic DNAmolecule produced by a method comprising 
the steps o f  
tagged DNA moleciles become attached to' said solid sur- 
face. 1s 
40. An enzymatic DNA molecule comprising a deoxyri- 
bonucleotide polymer having a catalytic activity for cleaving 
a nucleic acid-containing substrate to produce a cleavage 
product said enzymatic DNA molecule produced by a 
a. admixing a population of single-stranded DNA mol- 
ecules with ribonucleotide-containing substrate nucleic 
acid molecules to form an admixture; 
b. maintaining said admixture for a sufficient period of 
time and under predetermined reaction conditions to 2s 
allow single-stranded DNA molecules in said popula- 
tion to cause cleavage of said substrate nucleic acid 
molecules, thereby producing substrate cleavage prod- 
ucts; and 
method comprising the steps of  20 
a. admixing a population of single-stranded DNA mol- 
ecules with ribonucleotide-containing substrate nucleic 
acid molecules, to form an admixture; 
b. maintaining said admixture for a sufficient period of 
C 
- 
time and under predetermined reaction conditions to 
allow single-stranded DNA molecules in said popula- 
tion to-cause cleavage of said substrate nucleic acid 
molecules, thereby producing substrate cleavage prod- 
ucts; and 
isolating single-stranded DNA molecules that cleave 
said substrate nucleic acid molecules from said popu- 
lation. 
* * * * *  
